WO2003072046A2 - Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances - Google Patents

Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances Download PDF

Info

Publication number
WO2003072046A2
WO2003072046A2 PCT/US2003/005525 US0305525W WO03072046A2 WO 2003072046 A2 WO2003072046 A2 WO 2003072046A2 US 0305525 W US0305525 W US 0305525W WO 03072046 A2 WO03072046 A2 WO 03072046A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
controlled substance
hydrocodone
peptide
naltrexone
Prior art date
Application number
PCT/US2003/005525
Other languages
French (fr)
Other versions
WO2003072046A3 (en
Inventor
Thomas Piccariello
Randal J. Kirk
Original Assignee
New River Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New River Pharmaceuticals Inc. filed Critical New River Pharmaceuticals Inc.
Priority to EP03716144.5A priority Critical patent/EP1531844B1/en
Priority to AU2003219863A priority patent/AU2003219863C1/en
Priority to CA2477004A priority patent/CA2477004C/en
Priority to KR1020047013136A priority patent/KR100822498B1/en
Priority to JP2003570793A priority patent/JP4878732B2/en
Priority to IL16366703A priority patent/IL163667A0/en
Priority to CA2740256A priority patent/CA2740256A1/en
Priority to ES03716144.5T priority patent/ES2500117T3/en
Publication of WO2003072046A2 publication Critical patent/WO2003072046A2/en
Priority to US10/858,526 priority patent/US7105486B2/en
Priority to IL163667A priority patent/IL163667A/en
Priority to US10/923,257 priority patent/US7622441B2/en
Priority to US10/953,116 priority patent/US7375082B2/en
Priority to US10/953,111 priority patent/US20070066537A1/en
Publication of WO2003072046A3 publication Critical patent/WO2003072046A3/en
Priority to US11/089,056 priority patent/US20060014697A1/en
Priority to US11/179,801 priority patent/US8133881B2/en
Priority to US11/400,304 priority patent/US7700561B2/en
Priority to US12/131,923 priority patent/US7659253B2/en
Priority to US12/201,982 priority patent/US7674774B2/en
Priority to US12/201,820 priority patent/US20090137673A1/en
Priority to US12/201,907 priority patent/US7713936B2/en
Priority to US12/202,067 priority patent/US7687467B2/en
Priority to US12/202,146 priority patent/US7678771B2/en
Priority to US12/201,794 priority patent/US7687466B2/en
Priority to US12/201,760 priority patent/US7655630B2/en
Priority to US12/202,159 priority patent/US7671031B2/en
Priority to US12/201,586 priority patent/US7659254B2/en
Priority to US12/202,096 priority patent/US7718619B2/en
Priority to US12/201,866 priority patent/US7662788B2/en
Priority to US12/201,950 priority patent/US7671030B2/en
Priority to US12/201,739 priority patent/US7678770B2/en
Priority to US12/202,003 priority patent/US7723305B2/en
Priority to US12/202,941 priority patent/US20090137487A1/en
Priority to US12/203,134 priority patent/US20090137491A1/en
Priority to US12/203,058 priority patent/US20090143306A1/en
Priority to US12/202,955 priority patent/US20090143305A1/en
Priority to US12/202,987 priority patent/US20090192093A1/en
Priority to US12/203,133 priority patent/US20090137490A1/en
Priority to US12/203,136 priority patent/US20090209471A1/en
Priority to US12/203,132 priority patent/US20090137489A1/en
Priority to US12/202,699 priority patent/US20090131322A1/en
Priority to US12/203,108 priority patent/US20090181898A1/en
Priority to US12/231,489 priority patent/US20090143307A1/en
Priority to US12/202,845 priority patent/US20090137486A1/en
Priority to US12/203,127 priority patent/US20090131332A1/en
Priority to US12/203,129 priority patent/US20090137488A1/en
Priority to US12/203,137 priority patent/US20090149392A1/en
Priority to US12/202,777 priority patent/US20090143304A1/en
Priority to US12/239,221 priority patent/US20090131324A1/en
Priority to US12/239,571 priority patent/US20090137461A1/en
Priority to US12/239,364 priority patent/US20090137515A1/en
Priority to US12/239,600 priority patent/US20090137677A1/en
Priority to US12/239,400 priority patent/US20090186945A1/en
Priority to US12/239,087 priority patent/US20090186828A1/en
Priority to US12/239,554 priority patent/US20090131335A1/en
Priority to US12/239,154 priority patent/US20090131323A1/en
Priority to US12/239,247 priority patent/US20090131333A1/en
Priority to US12/239,479 priority patent/US20090131334A1/en
Priority to US12/239,238 priority patent/US20090131325A1/en
Priority to US12/239,577 priority patent/US20090131326A1/en
Priority to US12/239,429 priority patent/US20090131476A1/en
Priority to US12/239,180 priority patent/US20090186825A1/en
Priority to AU2008229978A priority patent/AU2008229978B2/en
Priority to US12/701,483 priority patent/US20110009669A1/en
Priority to US12/756,773 priority patent/US20100197798A1/en
Priority to US12/881,008 priority patent/US8343927B2/en
Priority to US13/339,095 priority patent/US20120115950A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to novel pharmaceutical compounds and more particularly to controlled substances that are covalently bound to a chemical moiety and thus rendered pharmaceutically inactive until broken down by enzymatic and/or chemical means in a time-dependent manner following oral administration. Delayed release from the conjugate prevents spiking of drug levels and affords gradual release over an extended period of time.
  • the enzymatic and/or chemical conditions necessary for the release of the controlled substance are either not present or of minimal activity when the novel pharmaceutical compound is introduced nasally, inhaled, or injected; thus, also preventing spiking when administered by these routes. Controlled substances with these novel properties are less likely to be abused due to the diminished "rush" effect of the modified controlled substance. Consequently, the therapeutic value of these pharmaceuticals is enhanced by decreasing euphoria while increasing the duration of the analgesic effect.
  • a number of pharmacologically useful compounds are also commonly abused controlled substances.
  • analgesics that are prescribed for the management of acute and chronic pain have become increasingly abused over the last decades.
  • Amphetamines are another example of controlled substances with important pharmacological uses that are highly addictive and commonly abused.
  • the present invention comprises a controlled substance that has been rendered inactive or substantially inactive comprising said controlled substance covalently bonded to a chemical moiety comprising an amino acid or more preferably an oligopeptide.
  • the oligopeptide preferably less than 50 and more preferably less than 6 amino acids.
  • the present invention comprises a controlled substance that has been rendered inactive or substantially inactive comprising said controlled substance covalently bonded to a chemical moiety comprising an amino acid or more preferably an oligopeptide which breaks down under the acid conditions of the stomach and/or the enzymatic activity present in the gastrointestinal tract.
  • absorption of the controlled substance into the bloodstream upon oral delivery occurs in a sustained release manner and peak concentrations of the drug are decreased as compared to non- conjugated drug given in a similar dosage and formulation.
  • Sustained release may further be defined as release of the active agent into systemic blood circulation over a prolonged period of time relative to the release of the active agent in conventional formulations through similar delivery routes.
  • the present invention relates to a method for delivering a controlled substance to a patient so as to obtain a therapeutic, but not a substantial euphoric effect, comprising orally administering the above composition to the patient.
  • the present invention relates to a method for delivering a controlled substance to a patient so as to obtain a therapeutic, but not a substantial euphoric effect, comprising parenterally administering the above composition to the patient.
  • Fig. 1. illustrates the synthesis of polyserine-naltrexone (carbonate- linked) conjugates
  • Fig. 2. illustrates mean serum concentration curves of rats orally dosed with BB272 polyserine-naltrexone conjugate vs. naltrexone;
  • Fig. 3. illustrates mean serum concentration curves of rats orally dosed with BB301polyserine-naltrexone vs. naltrexone (equal dose) vs. naltrexone
  • Fig. 4. illustrates Hydrocodone vs. Ethylcarbonate/Hydrocodone conjugates serum concentration curves
  • Fig. 5. illustrates how amino acid/narcotic conjugates may be synthesized
  • Fig. 6 illustrates Oxycodone vs. Glutamate/Oxycodone conjugate serum concentration curves
  • Fig. 7. illustrates Amphetamine vs. Glu-Amphetamine conjugate serum concentration curves
  • Fig. 9. illustrates Hydrocodone v. GGL-Hydrocodone conjugate serum concentration curves; [025] Fig. 10. illustrates Hydrocodone v. EEE-Hydrocodone conjugate serum concentration curves;
  • Fig. 11. illustrates Hydrocodone v. ribose-Hydrocodone conjugate serum concentration curves
  • FIG. 12. illustrates Hydrocodone v. E-Hydrocodone v. EE-
  • Fig. 13 illustrates Hydrocodone v. ribose-Hydrocodone conjugate serum concentration curves
  • Fig. 14. illustrates Hydrocodone vs. Butylated A-mino
  • Fig. 15. illustrates Paw Lick Latency vs. Time of ProProLeu-HC
  • Fig. 16. illustrates Paw Lick Latency vs. Time of LeuLeuLeu-HC v.
  • the present invention provides methods for altering controlled substances in a manner that decreases their potential for abuse.
  • the novel compounds may be combined in tablets with suitable excipients or formulated in solution for oral delivery.
  • the controlled substance When delivered by the oral route the controlled substance is released in a time-dependent manner (sustained release) by acid hydrolysis and/or enzymatic cleavage.
  • the controlled substance When administered by injection the controlled substance is released in a time-dependent manner (sustained release) by way of serum enzymes.
  • peptide is meant to include a single amino acid, a dipeptide, a tripeptide, an oligopeptide, a polypeptide, or the carrier peptide.
  • Oligopeptide is meant to include from 2 amino acids to 70 amino acids.
  • the invention is described as being an active agent attached to an amino acid, a dipeptide, a tripeptide, an oligopeptide, or polypeptide to illustrate specific embodiments for the active agent conjugate.
  • Preferred lengths of the conjugates and other preferred embodiments are described herein.
  • the number of amino acids is selected from 1, 2, 3, 4, 5, 6, or 7 amino acids.
  • the molecular weight of the carrier portion of the conjugate is below about 2,500, more preferably below about 1,000 and most preferably below about 500.
  • Controlled substance a substance subject to federal regulation of its manufacture, sale, or distribution because of the potential for, or proved evidence of, abuse; because of its potential for psychic or physiological dependence; because it constitutes a public health risk; because of the scientific evidence of its pharmacologic effect; or because of its role as a precursor of other controlled substances.
  • Chemical moiety a substance made up of chemical elements and characterized by a defined molecular composition. It can exist as a part of the drag conjugate and can be separated from the conjugate. Examples include an amino acid, an oligopeptide or a polypeptide, but may be any number of other substances.
  • compositions and methods of the present invention are likewise applicable to injectable administration of the controlled substance.
  • Covalent attachment of a chemical moiety to a controlled substance can render the substance pharmacologically inactive and resistant to absorption. Removal of the chemical moiety by enzymatic or chemical means, however, can restore the activity and the ability to be absorbed.
  • the acidic conditions of the stomach and/or the enzymatic activity present in the gastrointestinal tract can therefore affect release of the active controlled substance. Provided release does not occur too rapidly, the pharmacologically active agent will be absorbed into the bloodstream by a time-release mechanism following oral administration.
  • One aim of the invention is to decrease potential for abuse by establishing oral extended release via covalent modification. Although this would theoretically decrease the potential for abuse, ideally it would probably only decrease the potential by approximately half for oral administration.
  • the covalently modified compound of the invention (adopted for breakdown in the stomach or intestinal tract) is: i) not exposed to the necessary chemical and/or enzymatic conditions necessary for release of the active agent; or ii) the required activity is not present in sufficient amounts to affect rapid release/absorption.
  • the covalently modified controlled substance therefore, does not produce the euphoric effect sought by addicts.
  • opoid conjugate product that has a reasonable shelf life (shelf safe) which can not be abused through current practices. It is a preferred embodiment of the invention, however, that the opoid conjugate not release the opoid through chemical action prior to administration.
  • extended release (more accurately extended analgesia) may be achieved post absorption. This might be accomplished by: 1) extended serum half-life 2) extended CSF half-life 3) temporal absorption across the blood brain barrier (provided it is eventually converted to parent drug and does not have an adverse effect of its own).
  • the invention may be comprised of any controlled substance covalently attached to any chemical moiety, such as narcotics.
  • the controlled substance is an analgesic or stimulant.
  • the controlled substance is preferably of the group of analgesics comprised of the following: codeine, fentanyl, hydrocodone, hydromorphone, levorphanol, methadone, oxymorphone, morphine, oxycodone, propoxyphene, and sufentanyl.
  • the controlled substance may also be amphetamine or methylphenidate. Examples of other controlled drugs include barbiturates, benzodiazepines, skeletal muscle relaxants e.g. meprobamate, and stimulants including amphetamine, methamphetamine, methylphenidate, pemoline, etc.
  • the invention provides a carrier and active agent which are bound to each other but otherwise unmodified in structure.
  • This embodiment may further be described as the carrier having a free carboxy and/or amine terminal and/or side chain groups other than the location of attachment for the active agent.
  • the carrier whether a single -unino acid, dipeptide, tripeptide, oligopeptide or polypeptide is comprised only naturally occurring amino acids.
  • the chemical moiety comprising the invention may be any chemical substance that can be attached to the controlled substance in a manner that renders it pharmacologically inactive.
  • Analgesics and stimulants produce their pharmacological effects through binding to specific receptors or uptake proteins.
  • the attachment of certain chemical moieties can therefore prevent the active substance from binding its receptor(s) or recognition site on its uptake protein.
  • the covalent modification is believed to prevent the pharmacological effect by preventing the drug from crossing the blood- brain barrier.
  • the attachment of the chemical moiety to the controlled substance will also prevent or substantially delay the absorption of the compound, particularly when the compound is delivered by routes other than oral administration.
  • the attached chemical moiety is an amino acid or more preferably an oligopeptide.
  • the oligopeptide preferably comprises less than 50 amino acids and more preferably less than 6 amino acids.
  • the oligopeptide may comprise (i) a homopolymer of one of the twenty naturally occurring amino acids, (ii) a heteropolymer of two or more naturally occurring amino acids, (iii) a homopolymer of synthetic amino acids or (iv) a heteropolymer of two or more synthetic amino acids or (v) a heteropolymer of one or more naturally occurring amino acids and one or more synthetic amino acids.
  • the attached chemical moiety may be comprised of other naturally occurring or synthetic substances. Controlled substances, for example, could also be attached to lipids, carbohydrates, nucleic acids, or vitamins. These chemical moieties could be expected to serve the same functions as a polypeptide; namely, effect delayed release in the gastrointestinal tract and prevent rapid absorption of the active agent.
  • the covalently attached chemical moiety is removed by the acidic content of the stomach if the controlled substance is attached through an acid labile bond. More preferably, the covalently attached chemical moiety can be removed by enzymatic activity encountered by the compound in the stomach and/or intestinal tract.
  • the stomach and intestinal tract are bathed in degradative enzymes. For example, the pancreas releases into the small intestine a myriad of hydrolytic enzymes such as proteases, upases, and amylases, and nucleases. Additionally, the intestinal epithelial cells that line the surface of the GI tract produce various surface associated and intracellular degradative enzymes (e.g. brush border peptidases, esterases).
  • the controlled substance degrade proteins, lipids, carbohydrates, and nucleic acids contained in ingested food.
  • the chemical moiety is attached to the controlled substance in a manner in which it is not readily released by conditions found in the mouth (saliva), the intranasal cavity, the surface of the lungs, or in the serum. Extreme acid conditions encountered in the stomach are not present elsewhere in humans. Therefore, any acid dependent release mechanism will occur only after oral administration.
  • degradative enzymes are present in the aforementioned environments, they are not generally present in the high concentrations found in the intestinal tract. Thus, release of the controlled substance by enzymatic cleavage will not occur rapidly when the novel compounds are administered by routes other than oral delivery.
  • the analgesic e.g. oxycodone or hydrocodone
  • a polymer of serine or other amino acid containing a hydroxyl side chain e.g. threonine, tyrosine
  • attachment is to a polymer of glutamic acid through the carboxyl group of the delta carbon of glutamic acid.
  • the resulting ester (carbonate) linkages can be hydrolysed by lipases (esterases) encountered in the small intestine. Esterases are not present at high levels in saliva or on the mucosal surfaces of the nasal cavity, lungs, or oral cavity. Thus, controlled substances attached to polyglutamic acid by this method would not be rapidly released by saliva or when delivered intranasally or by inhalation.
  • the analgesic is attached to an oligopeptide, preferably consisting of between one and five amino acids.
  • the amino acids are a heterogenous mixture of the twenty naturally occurring amino acids. Hydrophilic amino acids will tend to prevent passive absorption of the analgesic peptide conjugate through nasal membranes.
  • hydrophilic amino acids be included in the oligopeptide.
  • lipophilic amino acids be attached closer to the analgesic for optimum stability. Both lipophilic and hydrophilic properties (i.e., amphiphilic) can be satisfied with between three and five amino acids.
  • the oligopeptide that is attached to the analgesic be an amphiphilic tripeptide.
  • Preferred amphiphilic amino acids/oligopeptides may be selected from (i) hydrophobic amino acids, preferably in positions next to the active agent to provide increased stability; (ii) amino acid sequences designed to be cleaved by intestinal enzymes (e.g. pepsin, trypsin, chymotrypsin, elastase, carboxypeptidases A and B, etc.) provide for increased bioavailability; (iii) peptides longer than three amino acids for increased stability, increased anti-abuse e.g. less membrane permeability, and potentially more efficient intestinal digestion e.g. major intestinal enzymes target proteins and polypeptides, (iv) or mixtures thereof.
  • intestinal enzymes e.g. pepsin, trypsin, chymotrypsin, elastase, carboxypeptidases A and B, etc.
  • intestinal enzymes e.g. pepsin, trypsin, chymotrypsin, e
  • the carrier portion of the conjugate is designed for intestinal cleavage.
  • the cleavage specificity is directed to pepsin and/or chymotrypsin.
  • preferred carriers include XXXAA or XXAAA, where X is selected from any amino acid, except Arg, Lys, His, Pro, and Met and A is selected from Tyr, Phe, Tip, or Leu.
  • more preferred carriers are selected from XXXPheLeu wherein X is Glu; XXXPheLeu wherein X is Gly; XXPheLeuLeu wherein X is Glu; and XXPheLeuLeu wherein X is Gly.
  • the cleavage specificity is directed to trypsin.
  • Examples of preferred carriers include XXXAA or XXAAA wherein X is any amino acid except Pro and Cys and A is Arg or Lys.
  • Examples of more preferred carriers are selected from XXXArgLeu wherein X is Glu; XXXArgLeu wherein X is Gly; XXArgLeuLeu wherein X is Gly; XXXArgLeuLeu wherein X is Gly.
  • the present invention provides covalent attachment of active agents to a peptide.
  • the invention may be distinguished from the above mentioned technologies by virtue of covalently attaching the active agent directly, which includes, for example, pharmaceutical drugs and nutrients, to the N-terminus, the C- terminus or to the side chain of an amino acid, an oligopeptide or a polypeptide, also referred to herein as a carrier peptide.
  • the active agent directly, which includes, for example, pharmaceutical drugs and nutrients, to the N-terminus, the C- terminus or to the side chain of an amino acid, an oligopeptide or a polypeptide, also referred to herein as a carrier peptide.
  • the invention provides a composition comprising a peptide and an active agent covalently attached to the peptide.
  • the peptide is (i) an oligopeptide, (ii) a homopolymer of one of the twenty naturally occurring amino acids (L or D isomers), or an isomer, analogue, or derivative thereof, (iii) a heteropolymer of two or more naturally occurring amino acids (L or D isomers), or an isomer, analogue, or derivative thereof, (iv) a homopolymer of a synthetic amino acid, (v) a heteropolymer of two or more synthetic amino acids or (vi) a heteropolymer of one or more naturally occurring amino acids and one or more synthetic amino acids.
  • compositions comprising a carrier peptide and an active agent covalently attached to the carrier peptide.
  • the carrier peptide is (i) an amino acid, (ii) a dipeptide, (iii) a tripeptide, (iv) an oligopeptide, or (v) polypeptide.
  • the carrier peptide may also be (i) a homopolymer of a naturally occurring amino acids, (ii) a heteropolymer of two or more naturally occurring amino acids, (iii) a homopolymer of a synthetic amino acid, (iv) a heteropolymer of two or more synthetic amino acids, or (v) a heteropolymer of one or more naturally occurring amino acids and one or more synthetic amino acids.
  • the invention further provides a composition comprising a single amino acid, a dipeptide or a tripeptide with an active agent covalently attached.
  • the amino acid, dipeptide or tripeptide are (i) one of the twenty naturally occurring amino acids (L or D isomers), or an isomer, analogue, or derivative thereof, (ii) two or more naturally occurring amino acids (L or D isomers), or an isomer, analogue, or derivative thereof, (iii) a synthetic amino acid, (iv) two or more synthetic amino acids or (v) one or more naturally occurring amino acids and one or more synthetic amino acids.
  • the amino acids are selected from L-amino acids for digestion by proteases.
  • the peptide carrier can be prepared using conventional techniques. A preferred technique is copolymerization of mixtures of amino acid N-carboxyanhydrides.
  • the peptide in another embodiment, can be prepared through a fermentation process of recombinant microorganisms followed by harvesting and purification of the appropriate peptide.
  • an automated peptide synthesizer can be used to produce a peptide with specific physicochemical properties for specific performance characteristics.
  • direct attachment of an active agent to the carrier peptide may not form a stable compound therefore the incorporation of a linker between the active agent and the peptide is required.
  • the linker should have a functional pendant group, such as a carboxylate, an alcohol, thiol, oxime, hydraxone, hydrazide, or an amine group, to covalently attach to the carrier peptide.
  • the invention also provides a method for delivering an active agent to a patient, the patient being a human or a non-human animal, comprising administering to the patient a composition comprising a peptide and an active agent covalently attached to the peptide.
  • the active agent is released from the composition by enzyme catalysis. In another preferred embodiment, the active agent is released in a time-dependent manner based on the pharmacokinetics of the enzyme-catalyzed release.
  • the active agent conjugates can incorporate adjuvants such that the compositions are designed to interact with specific receptors so that targeted delivery may be achieved. These compositions provide targeted delivery in all regions of the gut and at specific sites along the intestinal wall.
  • the active agent is released as the reference active agent from the peptide conjugate prior to entry into a target cell.
  • the specific amino acid sequences used are not targeted to specific cell receptors or designed for recognition by a specific genetic sequence.
  • the peptide carrier is designed for recognition and/or is not recognized by tumor promoting cells.
  • the active agent delivery system does not require that the active agent be released within a specific cell or intracellularly.
  • the carrier and/or the conjugate do result is specific recognition in the body. (e.g. by a cancer cell, by primers, for improving chemotactic activity, by sequence for a specific binding cite for serum proteins(e.g. kinins or eicosanoids).
  • the active agent may be attached to an adjuvant recognized and taken up by an active transporter.
  • the active transporter is not the bile acid active transporter.
  • the present invention does not require the attachment of the active agent to an adjuvant recognized and taken up by an active transporter for delivery.
  • the active agent conjugate is not bound to an immobilized carrier, rather it is designed for transport and transition through the digestive system.
  • microsphere/capsules may be used in combination with the compositions of the invention, the compositions are preferably not incorporated with microspheres/capsules and do not require further additives to improve sustained release.
  • the active agent is not a hormone, glutamine, methotrexate, daunorabicin, a trypsin-kallikrein inhibitor, insulin, calmodulin, calcitonin, L-dopa, interleukins, gonadoliberin, norethindrone, tolmetin, valacyclovir, taxol, or silver sulfadiazine.
  • the active agent is a peptidic active agent it is preferred the active agent is unmodified
  • the invention provides a carrier and active agent which are bound to each other but otherwise unmodified in structure.
  • the carrier whether a single amino acid, dipeptide, tripeptide, oligopeptide or polypeptide is comprises only naturally occurring amino acids.
  • the carrier is not a protein transporter (e.g. histone, insulin, transferrin, IGF, albumin or prolactin), Ala, Gly, Phe-Gly, or Phe-
  • protein transporter e.g. histone, insulin, transferrin, IGF, albumin or prolactin
  • the carrier is also preferably not a amino acid copolymerized with a non-amino acid substitute such as PNP, a poly(alkylene oxide) amino acid copolymer, or an alkyloxycarbonyl (polyaspartate/polyglutamate) or an aryloxycarbonylmethyl (polyaspartate/polyglutamate).
  • a non-amino acid substitute such as PNP, a poly(alkylene oxide) amino acid copolymer, or an alkyloxycarbonyl (polyaspartate/polyglutamate) or an aryloxycarbonylmethyl (polyaspartate/polyglutamate).
  • neither the carrier or the conjugate are used for assay purification, binding studies or enzyme analysis.
  • the carrier peptide allows for multiple active agents to be attached.
  • the conjugates provide the added benefit of allowing multiple attachments not only of active agents, but of active agents in combination with other active agents, or other modified molecules which can further modify delivery, enhance release, targeted delivery, and/or enhance adsorption.
  • the conjugates may also be combined with adjuvants or be microencapsulated.
  • the composition of the invention is in the form of an ingestible tablet or capsule, an intravenous preparation, an intramuscular preparation, a subcutaneous preparation, a depot implant, a transdermal preparation, an oral suspension, a sublingual preparation, an intranasal preparation, inhalers, or anal suppositories.
  • the peptide is capable of releasing the active agent from the composition in a pH-dependent manner.
  • the active agent is prepared and/or administered through means other than implantation and/or injectables.
  • Embodiments of the present invention preferably are not bound to an adjuvant recognized and/or taken up by active transporters.
  • the active agent conjugates of the present invention are not attached to active transporters, or antigenic agents such as receptor recognizing sequences found on cells and tumors.
  • the active agent conjugate of the present invention is not connected to or constitutes an implantable polymer, which would not biodegrade in less than 48 hours, preferably between 12 and 24 hours.
  • the active agent conjugates of the present invention are preferably designed to release the active agent into the blood, after absorption from the gut, as the reference active agent.
  • One embodiment of the invention relates to long acting narcotic drugs having significantly reduced abuse potential.
  • the active agent is covalently bound to a peptide/oligopeptide or amino acid, which renders the active agent pharmaceutically inactive until released.
  • the release mechanism is enzymatic action. Following oral administration the intestinal enzymes release the drug.
  • the enzymatic and/or chemical conditions necessary for the release of the controlled substances is either not present or is minimally active when the drug- peptide conjugate is introduced by inhalation or injection. Thus it is expected that no euphoric effect will occur when the drug-peptide conjugate is inhaled or injected.
  • the invention also provides for reproducible methods for compositions which are abuse-free for controlled substances, stable under a variety of chemical conditions, reduced euphoric effect and extended absorption into the bloodstream.
  • Naltrexone an opoid antagonist
  • Naltrexone was chosen as a model compound for testing conjugates for the hypothesis that conjugates of opoid drugs can afford extended release, while also lowering the potential for abuse.
  • Naltrexone is chemically similar to orally delivered analgesics such as oxycodone and hydromorphone and therefore amenable to synthesizing conjugates for testing in vitro and in vivo performance.
  • N-acetylated polyserine-methyl ester (0.69 g, 7.9 rnmol) was dissolved in N-methylpyrolidinone (15 ml) and allowed to stir under argon at ambient temperature. Carbonyldiimmidazole (GDI, 1.93g, 11.9mmol) was added and the reaction allowed to stir over night under argon. Then, 100 ml of acetonitrile were added and the mixture allowed to sit at 4 °C for 2 hours. The precipitate that formed was collected by centrifugation and the resulting pellet then resuspended in acetonitrile. This suspension was then centrifuged and the pellet dried over night under a vacuum.
  • GDI Carbonyldiimmidazole
  • Tetrabutylammonium salt of naltrexone Naltrexone hydrochloride (1.5g, 3.979mmol) was dissolved in water ( ⁇ 50ml) and this solution titrated with IN LiOH to a pH of -11-12. Tetrabutylammonium chloride (2.6g, 4.0mmol) was then added. The aqueous solution was then extracted with 3 equal volumes of chloroform (20ml each). The organic solutions were pooled and dried with magnesium sulfate. The solvent was then removed using a rotovap, and the resulting solid dried over night under a high vacuum.
  • naltrexone in the polyserine-naltrexone conjugate BB272 was estimated to be 30% as based on the 1:6 ratio of naltrexone:serine determined by NMR.
  • Polyserine-naltrexone conjugate was given to four rats at a dose of 12 mg which contained 3.6 mg of naltrexone.
  • Doses of naltrexone (3.6 mg) equivalent to the naltrexone content of the conjugate were also given to four rats.
  • Capsules were delivered orally to rats at time-zero using a capsule dosing syringe.
  • Seram was collected from rats 2, 4, 6, 9, and 12 hours after capsule delivery.
  • Seram naltrexone concentrations were determined by ELISA using a commercially available kit (Nalbuphine, product #102819, Neogen Corporation, Lansing MI).
  • Serum levels of individual animals are shown in Table 1. Mean serum levels are shown in Table 3. (Example 2). As shown in Fig. 2, serum levels spiked earlier for naltrexone (2 hours) than for the drug administered as a polyserine-naltrexone conjugate (4 hours). Serum levels of naltrexone for the polyserine-naltrexone conjugate remained elevated considerably longer than for naltrexone. Additionally, the peak level was significantly lower for the polyserine- naltrexone conjugate. It should be noted that the 2 hour time point was the first measurement of naltrexone seram levels. Since this was the peak level measured for naltexone it can not be determined whether or not levels peaked at a higher concentration earlier. Consequently, it was not possible to accurately determine the C ma x or area under serum concentration curve (AUC) for naltrexone in this experiment.
  • Example 3 In vivo performance of polyserine-naltrexone conjugate
  • naltrexone in the polyserine-naltrexone conjugate BB272 was estimated to be 30% as based on the 1:6 ratio of naltrexone :serine determined by NMR.
  • Polyserine-naltrexone conjugate was given to five rats at a dose of 12.9 mg which contained 3.6 mg of naltrexone.
  • Doses equivalent to the naltrexone contained in the batch of polyserine-naltrexone (BB 301) were also given to five rats. Additionally, half the equivalent dose (1.8 mg) was given at time-zero, followed by a second half-dose at 6.5 hours to five rats.
  • Capsules were delivered orally to rats at time-zero using a capsule delivery syringe.
  • Seram was collected at 0.5, 1.5, 3, 5, 8, 12, 15 and 24 hours after capsule delivery for the polyserine-naltrexone (BB301) and equivalent naltrexone dosed rats.
  • Serum was collected at 0.5, 1.5, 3, 5, 8, 11.5, 14.5 and 24 hours after capsule delivery for rats dosed with half-equivalent doses at 0 and 6.5 hours.
  • Seram naltrexone concentrations were determined by ELISA using a commercially available kit (Nalbuphine, product #102819, Neogen Corporation, Lansing MI).
  • the mean time to peak concentration (T max ) was significantly longer for the polyserine-naltrexone conjugate (Table 4).
  • the mean AUC of the polyserine- naltrexone conjugate was approximately 75% of the naltrexone mean AUC (Table 4).
  • Statistically the mean AUCs were not significantly different (P ⁇ 0.05).
  • Seram levels of rats fed one-half-dose (1.8 mg) at time zero and at 6.5 hours were compared to those of rats fed polyserine-naltrexone conjugate. Concentration levels remained elevated for the conjugate past those for the second naltrexone dose, with the curves crossing at approximately 2.5 hours and again at approximately 11 hours (double cross-over of the serum concentration curves).
  • a synthesized analog of hydrocodone was prepared by reaction of the enolate of hydrocodone with ethylchloroformate. The hydrocodone portion was not released under a wide range of pH's and temperatures. EtOCOhydrocodone was studied in a rat model and its pharmacokinetics was nearly identical to that of the reference drag ( Figure 4). Ethoxycarbonylhydrocodone's AUC is 90% of hydrocodone' s AUC. EtOCOhydrocodone meets the criteria for an abuse-free narcotic (i.e., stability and in vivo release) when injected.
  • an abuse-free narcotic i.e., stability and in vivo release
  • FIG. 5 shows a general scheme for how amino acid narcotic conjugates are synthesized using oxycodone and hydrocodone as examples.
  • the anion of oxycodone (or hydrocodone) was reacted with the protected N-hydroxysuccinimide ester (OSu) of the respective amino acid, which is fully deprotected in HCl/dioxane to yield the final product.
  • OSu protected N-hydroxysuccinimide ester
  • example 4 shows that carbonate linked compounds are substantially resistant to release of naltrexone by exposure to acid, base and protease.
  • Other opoid conjugates can be synthesized in a similar manner to obtain similar characteristics.
  • Example 5 provides an additional method of synthesis by which opoid carbonate conjugates can be synthesized. In particular, this method allows for conjugation to oxycodone via a carbonate linkage.
  • Example 6 Synthetic Protocol for Amino Acid Conjugate of (S)-amphetamine
  • Peptide-amphetamine conjugates and an equivalent amount of parent amphetamine contained in the conjugate were orally administered separately to male Sprague-Dawley rats (-250 g). Drugs were delivered as oral solutions in water. The amphetamine content of each conjugate was determined by NMR analysis. Serum levels of amphetamine were analyzed by ELISA (Neogene, Lexington, KY, Amphetamine kit. 109319).
  • GluGlu-amphetamine and Phe-amphetamine had nearly equal C max and AUC to those of the parent drug (Table 5).
  • the serum concentration curves are shown in Fig. 8. No change in the shape of the curve was observed for the amphetamine conjugates.
  • Peptide-narcotic conjugates and an equivalent amount of parent narcotic (hydrocodone or oxycodone) contained in the conjugate were orally administered separately to male Sprague-Dawley rats (-250 g). Drugs were delivered as oral solutions in water or phosphate buffered saline or as solids in gelatin capsules. The narcotic content of each conjugate was determined by HPLC analysis. Serum levels of hydrocodone and oxycodone were analyzed by ELISA (Neogene, Lexington, KY, Oxymorphone/Oxycodone kit. 102919 and Hydromorphone/ ⁇ ydrocodone kit. 106610-1).
  • narcotic conjugates have been tested for oral bioavailability vs. the parent drug. These include 13 peptide conjugates, 2 monosaccharide conjugates, and 2 lipid conjugates. Eleven of the nine peptide conjugates had 60% or greater bioavailability based on AUC. Examples, which when compared to an equivalent dose of the parent drug, include: Glu-Oxycodone which was 121% bioavailable (Fig. 6); GlyGlyLeu- Hydrocodone which was 82% bioavailable (Fig. 9), and GluGluGlu-HC which was 117% bioavailable (Fig. 10). The Ribose-HC conjugate had 106% when compared to an equivalent dose of the parent drag (Fig 11).
  • a sustained release profile was observed with one of the amino acid conjugates Glu-Oxycodone (Fig. 6).
  • the compound showed a blunted curve (decrease in C max ) combined with a 2- fold increase in time to peak concentration (T max ) and approximately equivalent AUC.
  • Glu-Oxycodone is not sufficiently stable to warrant consideration as an anti-abuse product.
  • No other narcotics compounds tested to date showed sustained release kinetics with equal AUC.
  • One other compound, protected Glu-Leu-HC showed an increase in T max without equal AUC.
  • the IN model was used to test the absorption of EEE-HC in water and in saline (PBS, pH 7.4).
  • PBS saline
  • the inhibition of IN absorption was more significantly inhibited in PBS than in water. Therefore other compounds should be tested in the IN model in water and perhaps other buffers.
  • BocGlu(OtBu)hydrocodone and 6-O-BocLys(NHBoc)-hydrocodone which are completely stable in water at room temperature and under heated conditions as shown in Table 8 and Table 9.
  • the conjugates are also stable at a wide range of pH's.
  • the stability of the amino acid/narcotic conjugates can be increased by tethering it to a larger peptide via the nitrogen on the amino acid residue. This will also extend the absorption of the orally administered drag.
  • the dipeptides added to hydrocodone include GluGlu, LeuGlu, AlaPro, GluPro and GluLeu.
  • Example 14 Analgesia of GlvGlvGlu-HC and ProProLeu-HC vs. HC Subcutaneously Injected
  • Peptide-narcotic conjugates GlyGlyGlu-HC and ProProLeu-HC and an equivalent amount of HC contained in the conjugates were subcutaneously administered separately to male Sprague-Dawley rats (-250 g).
  • the level of analgesia was scored by the PLL (paw lick latency) method using the hot plate nociceptive model as described (Tomkins, D.M., et al. J Pharmacol Experimental Therapeutics, 1997, 280:1374-1382).
  • Table 10 shows the latency response of GlyGlyGlu-HC vs. HC. Basal PLL times of untreated rats were subtracted from the conjugate and hydrocodone PLLs.
  • analgesia of GlyGlyGlu-HC was 54 % and at 45 minutes was 8 %, when PPLs above basal level were compared to HC indicating that analgesia was significantly inhibited by the attached tripeptide.
  • the latency response of ProProLeu-HC vs. HC is shown in Fig. 15 and Table 11. PLL times above 0 hour basal level of pretreated rats is was scored at 15, 30, 45, and 60 minutes. At the thirty minute peak of analgesia ProProLeu-HC was 9 % of that for hydrocodone. The PPL latency score of ProProLeu-HC gradually rose over time, however, at 60 minutes was still only 43% of the hydrocodone. (note: a cutoff time of 45 seconds was used in the PLL scoring in order to minimaize any harm to the animals. Most of the hydrocodone treated animals reached the maximum 45 seconds at peak analgesia).
  • GlyGlyGlyGlyGlyLeu-HC and GlyGlyGlyGly-HC (2X the equivalent dose) is shown in Table 12 and Fig. 16.
  • PLL times above 0 hour basal level of pretreated rats was scored at 15, 30, and 60 minutes. At the thirty minute peak of analgesia
  • hydrocodone was the only test group that showed any response.
  • the PPL latency scores of the peptide conjugates did not rise above the basal response, including the GlyGlyGlyGly-HC treated group that received twice the hydrocodone control dose.
  • the active agent that is attached to the carrier peptide can have one or more of different functional groups.
  • the functional groups include an amine, carboxylic acid, alcohol, ketone, amido (or its chemical equivalent), thiol or sulfate. Examples of these active agents, their functional groups and site of attachment to the carrier peptide is provided in the section below. One skilled in the art would recognize the techniques necessary to covalently attach a peptide to the active agents as described through the application.
  • Acetaminophen is a known pharmaceutical agent that is used in the treatment of minor aches and pains. Its chemical name is N-acetyl-p-aminophenol. It is often used in combination with codeine, whose chemical name is 7,8- didehydro-4,5- ⁇ -epoxy-3-methoxy- 17-methylmephorninan-6 ⁇ -ol. Both are commercially available and readily manufactured using published synthetic schemes by those of ordinary skill in the art.
  • both acetaminophen and codeine are covalently attached to the peptide via their hydroxyl groups.
  • Codeine is a known pharmaceutical agent that is used in the treatment of pain.
  • the composition of the invention comprises codeine covalently attached to a peptide.
  • codeine is covalently attached to the peptide via the hydroxyl group.
  • Dihydrocodeine is a known pharmaceutical agent that is used in the treatment of pain.
  • the composition of the invention comprises dihydrocodeine covalently attached to a peptide.
  • dihydrocodeine is covalently attached to the peptide via the hydroxyl group.
  • Codeine and guaifenesin is a known pharmaceutical agent that is used in the treatment of coughs.
  • the composition of the invention comprises codeine and guaifenesin covalently attached to a peptide via the hydroxyls of either active agent.
  • Codeine and promethazine are known pharmaceutical agents used in the treatment of coughs.
  • the composition of the invention comprises codeine and promethazine covalently attached to a peptide via functional groups specified in the active agent's respective catagory.
  • Codeine, guaifenesin and pseudoephidrine are known pharmaceutical agents used in the treatment of coughs.
  • the composition of the invention comprises codeine and promethazine covalently attached to a peptide via functional groups specified in the active agent's respective catagory.
  • Codeine, guaifenesin and pseudoephidrine are used in the treatment of coughs and colds.
  • the composition of the invention comprises codeine, guaifenesin and pseudoephidrine covalently attached to a peptide peptide via functional groups specified in the active agent's respective catagory.
  • Codeine, phenylephrine and promethazine is a known pharmaceutical agent that is used in the treatment of coughs and colds.
  • the composition of the invention comprises codeine, phenylephrine and promethazine covalently attached to a peptide via functional groups specified in the active agent's respective catagory.
  • Fentanyl is a known pharmaceutical agent that is used in the treatment of pain. It is both commercially available and readily manufactured using published synthetic schemes by those of ordinary skill in the art. Its structure is:
  • the fentanyl or modified fentanyl is covalently attached to the peptide via a linker.
  • This linker may be a small molecule containing 2-6 carbons and one or more functional groups (such as amines, amides, alcohols, or acids) or may be made up of a short chain of either amino acids or carbohydrates.
  • Acetaminophen and hydrocodone is a known pharmaceutical agent that is used in the treatment of pain.
  • the chemical name of acetaminophen is N- acetyl-p-aminophenol.
  • the composition of the invention comprises acetaminophen and hydrocodone covalently attached to a peptide.
  • Chlorpheniramine and hydrocodone is a known pharmaceutical agent that is used in the treatment of pain.
  • the composition of the invention comprises chlorpheniramine and hydrocodone covalently attached to a peptide.
  • Guaifenesin and hydrocodone is a known pharmaceutical agent that is used in the treatment of coughs.
  • the composition of the invention comprises guaifenesin and hydrocodone covalently attached to a peptide using functional groups specifally described in the active agents respective category.
  • Himatropine and hydrocodone is a known pharmaceutical agent that is used in the treatment of pain.
  • the composition of the invention comprises himatropine and hydrocodone covalently attached to a peptide using functional groups specifally described in the active agents respective category.
  • Hydrocodone and phenylpropanolamine are used in the treatment of coughs and colds.
  • the composition of the invention comprises hydrocodone and phenylpropanolamine covalently attached to a peptide.
  • hydrocodone and phenylpropanolamine is covalently attached to the peptide via one of the hydroxyl groups.
  • phenylpropanolamine can be covalently attached to the peptide via the amino group.
  • ibuprofen and hydrocodone are used in the treatment of pain.
  • the structure of ibuprofen is:
  • composition of the invention comprises ibuprofen and hydrocodone covalently attached to a peptide using functional groups specifically described in the active agents respective category.
  • Hydrocodone is a known pharmaceutical agent that is used in the treatment of pain.
  • the composition of the invention comprises hydrocodone covalently attached to a peptide.
  • hydrocodone is covalently attached to the peptide via a ketone group and a linker.
  • This linker may be a small linear or cyclic molecule containing 2-6 atoms with one or more heteroatoms and one or more functional groups (such as amines, amides, alcohols or acids). For example, glucose would be suitable as a linker.
  • hydrocodone may be attached directly through an enolate.
  • Hydromorphone is a known pharmaceutical agent that is used in the treatment of cough and pain. Its structure is:
  • composition of the invention comprises hydromorphone covalently attached to a peptide.
  • hydromorphone is covalently attached to the peptide via the hydroxyl group.
  • Morphine is a known pharmaceutical agent that is used in the treatment of pain. Its structure is:
  • composition of the invention comprises morphine covalently attached to a peptide.
  • morphine is covalently attached to the peptide via any of the hydroxyl groups.
  • Diacetylmorphine is a known pharmaceutical agent that is used in the treatment of pain.
  • the composition of the invention comprises diacetylmorphine covalently attached to a peptide.
  • diacetylmorphine or modified diacetylmorphine is covalently attached to the peptide via a linker.
  • This linker may be a small molecule containing 2-6 carbons and one or more functional groups (such as amines, amides, alcohols, or acids) or may be made up of a short chain of either amino acids or carbohydrates.
  • Dihydromorphine is a known pharmaceutical agent that is used in the treatment of pain.
  • the composition of the invention comprises dihydromorphine covalently attached to a peptide.
  • dihydromorphine is covalently attached to the peptide via the hydroxyl group.
  • Ethylmorphine is a known pharmaceutical agent that is used in the treatment of pain.
  • the composition of the invention comprises ethylmorphine covalently attached to a peptide.
  • ethylmorphine is covalently attached to the peptide via the hydroxyl group.
  • Oxycodone and acetaminophen are used together in the treatment of pain.
  • composition of the invention comprises oxycodone and acetaminophen covalently attached to a peptide.
  • Oxycodone is a known pharmaceutical agent that is used in the treatment of pain.
  • the structure of oxycodone is:
  • composition of the invention comprises oxycodone covalently attached to a peptide.
  • oxycodone is covalently attached to the peptide via a ketone group and a linker.
  • This linker may be a small linear or cyclic molecule containing 2-6 atoms with one or more heteroatoms and one or more functional groups (such as amines, amides, alcohols or acids). For example, glucose would be suitable as a linker.
  • oxycodone may be attached directly through an enolate.
  • Propoxyphene is a known pharmaceutical agent that is used in the treatment of pain. It is a mild narcotic analgesic. It is both commercially available and readily manufactured using published synthetic schemes by those of ordinary skill in the art. The structure of propoxyphene is
  • the composition of the invention comprises propoxyphene covalently attached to a peptide.
  • propoxyphene or modified propoxyphene is covalently attached to the peptide via a linker.
  • This linker may be a small molecule containing 2-6 carbons and one or more functional groups (such as amines, amides, alcohols, or acids) or may be made up of a short chain of either amino acids or carbohydrates.
  • Dextroamphetamine is a known pharmaceutical agent that is used in the treatment of narcolepsy and attention deficit hyperactivity disorder. It is both commercially available and readily manufactured using published synthetic schemes by those of ordinary skill in the art. Its structure is:
  • dextroamphetamine is covalently attached to the peptide via the amino group.
  • D-methylphenidate is a known pharmaceutical agent that is used in the treatment of attention deficit disorder. Its chemical name is ( R,2R)- ⁇ -phenyl- 2-piperidineacetic acid methyl ester. Its structure is:
  • D-methylphenidate is the subject of U.S. Patent Number 2,507,631
  • D-methylphenidate is covalently attached to the peptide via the amino group.
  • Methylphenidate is a known pharmaceutical agent that is used in the treatment of attention deficit disorder. Its structure is:
  • composition of the invention comprises methylphenidate covalently attached to a peptide.
  • methylphenidate is covalently attached to the peptide via the amino group.

Abstract

The present invention provides methods for altering controlled substances in a manner that decreases their potential for abuse. The novel compounds may be combined in tablets with suitable excipients or formulated in solution for oral delivery. When delivered by the oral route the controlled substance is released in a time-dependent manner (sustained release) by acid hydrolysis and/or enzymatic cleavage. When administered by injection the controlled substance is released in a time-dependent manner (sustained release) by way of serum enzymes.

Description

NOVEL SUSTAINED RELEASE PHARMACEUTICAL COMPOUNDS TO PREVENT ABUSE OF CONTROLLED SUBSTANCES
BACKGROUND OF THE INVENTION:
(i) Field of the invention
[001] The present invention relates to novel pharmaceutical compounds and more particularly to controlled substances that are covalently bound to a chemical moiety and thus rendered pharmaceutically inactive until broken down by enzymatic and/or chemical means in a time-dependent manner following oral administration. Delayed release from the conjugate prevents spiking of drug levels and affords gradual release over an extended period of time. The enzymatic and/or chemical conditions necessary for the release of the controlled substance are either not present or of minimal activity when the novel pharmaceutical compound is introduced nasally, inhaled, or injected; thus, also preventing spiking when administered by these routes. Controlled substances with these novel properties are less likely to be abused due to the diminished "rush" effect of the modified controlled substance. Consequently, the therapeutic value of these pharmaceuticals is enhanced by decreasing euphoria while increasing the duration of the analgesic effect.
(ii) Description of the Related Art
[002] A number of pharmacologically useful compounds are also commonly abused controlled substances. In particular, analgesics that are prescribed for the management of acute and chronic pain have become increasingly abused over the last decades. For example, the increase in prescription of oxycodone in the last few years led to widespread abuse of this drag. Amphetamines are another example of controlled substances with important pharmacological uses that are highly addictive and commonly abused.
[003] There is considerable information readily available to individuals which teaches how to derive purified forms of controlled substances from prescription products. These techniques are both simple and well described on multiple websites. Most of these procedures utilize cold water, although, hot water, changes in pH and other solvents are described. Examples of these procedures are described below.
[004] The description of these procedures was found on the web in
February of 2003 at http://codeine.50g.eom/info/extraction.html#ex.coldw and is paraphrased below. Cold water extraction is used to extract an opiate/opioid substance from combination tablets. This method subverts the fact that opiates are generally very soluble in cold water, while paracetamol, aspirin, and ibuprofen are only very slightly soluble. These techniques are sophisticated enough to recognize that pseudoephedrine and caffeine are water soluble and will remain in the solution and that dispersible tablets make it difficult to extract secondary substances. The description of the equipment required makes it clear that these procedures make abuse readily available. The equipment includes a minimum two glasses or cups, paper filters (unbleached coffee filters will do) and a measure glass. Portions of the procedures are provided below:
1. Crush the tablets and dissolve in cold (20° C) water.
2. Cool the solution down to approximately 5° C stirring occasionally.
3. Leave the solution in a cool place for about 20 minutes.
4. Wet the filter(s) with very cold water to prevent it from absorbing the solution and put it in the glass. Stick an elastic/rubber band around the container to keep the filter in place.
5. Pour the solution through the filter to filter out the secondary substance from codeine.
6. Discard used filters with secondary substance solids left.
[005] However, when these procedures were viewed as not providing sufficient yields improved method were designed for extracting codeine which simply require the addition of chloroform or like solvent such as methylene chloride. This technique utilizes methods which alter the pH aspects of the solution to improve extraction and even provides instruction on how to re-salt the product. Portions of the procedure are described below. 1. Place uncrushed T3's or other AEAE/codeine product in a small glass or beaker and cover with enough distilled water so that the pills will break down into a thin paste.
2. Add dry sodium carbonate to reduce the codeine phosphate to codeine base. The pH of the mixture should be about 11 or greater.
3. Pour the mixture into the pyrex pan and rinse the beaker with a few ml of distilled water and add the rinse water to the mix in a pan.
4. Wrap the dried material in a coffee filter and grind the stuff
5. Pour the dry crushed mixture into a glass bottle with a screw-on top and pour in enough chloroform to completely cover.
6. Shake and filter.
[006] While there has been considerable effort to provide controlled substances which are resistance to abuse current products fail to achieve the stability required to prevent abuse. The present invention however, provides methods and compositions which retain their stability even when subjected to current abuse methods, and therefore provide a much needed but less addictive and/or less likely to be abused product.
SUMMARY OF THE INVENTION
[007] Thus, there is clearly a need in the art for a more "street-safe" version of controlled substances, which will permit one to obtain the therapeutically beneficial effects of these substances on the one hand while avoiding the euphoric effects that lead to substance abuse on the other hand. It is, therefore, a primary object of the present invention to fulfill this need by providing controlled substances that have been chemically modified to be released only under selected conditions and, even then, only at a controlled rate that does not give rise to a euphoric effect.
[008] More particularly, it is an object of the present invention to provide chemically modified controlled release substances that are themselves inactive and resistant to absorption until broken down by chemical or enzymatic means at the desired target location, such as for example under the acidic conditions of the stomach and/or the enzymatic activity present in the gastrointestinal tract. [009] It is another object of the invention to provide chemically modified controlled release substances that are released only in the blood serum, again at controlled release rates that do not give rise to a euphoric effect.
[010] In a first aspect, the present invention comprises a controlled substance that has been rendered inactive or substantially inactive comprising said controlled substance covalently bonded to a chemical moiety comprising an amino acid or more preferably an oligopeptide. The oligopeptide preferably less than 50 and more preferably less than 6 amino acids.
[011] In a second aspect, the present invention comprises a controlled substance that has been rendered inactive or substantially inactive comprising said controlled substance covalently bonded to a chemical moiety comprising an amino acid or more preferably an oligopeptide which breaks down under the acid conditions of the stomach and/or the enzymatic activity present in the gastrointestinal tract.
[012] In the oral composition define above, absorption of the controlled substance into the bloodstream upon oral delivery occurs in a sustained release manner and peak concentrations of the drug are decreased as compared to non- conjugated drug given in a similar dosage and formulation. Sustained release may further be defined as release of the active agent into systemic blood circulation over a prolonged period of time relative to the release of the active agent in conventional formulations through similar delivery routes.
[013] In a third aspect, the present invention relates to a method for delivering a controlled substance to a patient so as to obtain a therapeutic, but not a substantial euphoric effect, comprising orally administering the above composition to the patient. [014] In a fourth aspect, the present invention relates to a method for delivering a controlled substance to a patient so as to obtain a therapeutic, but not a substantial euphoric effect, comprising parenterally administering the above composition to the patient.
[015] The invention is further illustrated by drawings (figures) and tables of data. The following is a list of illustrations describing the invention in detail.
BRIEF DESCRIPTION OF THE DRAWINGS
[016] Fig. 1. illustrates the synthesis of polyserine-naltrexone (carbonate- linked) conjugates;
[017] Fig. 2. illustrates mean serum concentration curves of rats orally dosed with BB272 polyserine-naltrexone conjugate vs. naltrexone;
[018] Fig. 3. illustrates mean serum concentration curves of rats orally dosed with BB301polyserine-naltrexone vs. naltrexone (equal dose) vs. naltrexone
(1/2 dose at 0 hours and at 6.5 hours);
[019] Fig. 4. illustrates Hydrocodone vs. Ethylcarbonate/Hydrocodone conjugates serum concentration curves;
[020] Fig. 5. illustrates how amino acid/narcotic conjugates may be synthesized;
[021] Fig. 6 illustrates Oxycodone vs. Glutamate/Oxycodone conjugate serum concentration curves;
[022] Fig. 7. illustrates Amphetamine vs. Glu-Amphetamine conjugate serum concentration curves;
[023] Fig. 8. Serum concentration curves of peptide-amphetamine conjugates vs. amphetamine;
[024] Fig. 9. illustrates Hydrocodone v. GGL-Hydrocodone conjugate serum concentration curves; [025] Fig. 10. illustrates Hydrocodone v. EEE-Hydrocodone conjugate serum concentration curves;
[026] Fig. 11. illustrates Hydrocodone v. ribose-Hydrocodone conjugate serum concentration curves;
[027] Fig. 12. illustrates Hydrocodone v. E-Hydrocodone v. EE-
Hydrocodone v. EEE-Hydrocodone v. EpE-Hydrocodone v. GGL-Hydrocodone conjugate serum concentration curves;
[028] Fig. 13. illustrates Hydrocodone v. ribose-Hydrocodone conjugate serum concentration curves;
[029] Fig. 14. illustrates Hydrocodone vs. Butylated A-mino
Acid Hydrocodone Conjugates Serum Concentration Curves;
[030] Fig. 15. illustrates Paw Lick Latency vs. Time of ProProLeu-HC and
Hydrocodone; and
[031] Fig. 16. illustrates Paw Lick Latency vs. Time of LeuLeuLeu-HC v.
ProProLIIe-HC v. GlyGlyGlyGlyLeu-HC v. GlyGlyGlyGlyLeu-HC(2x) v.
Hydrocodone.
DETAILED DESCRIPTION
[032] The present invention provides methods for altering controlled substances in a manner that decreases their potential for abuse. The novel compounds may be combined in tablets with suitable excipients or formulated in solution for oral delivery. When delivered by the oral route the controlled substance is released in a time-dependent manner (sustained release) by acid hydrolysis and/or enzymatic cleavage. When administered by injection the controlled substance is released in a time-dependent manner (sustained release) by way of serum enzymes. [033] Throughout this application the use of "peptide" is meant to include a single amino acid, a dipeptide, a tripeptide, an oligopeptide, a polypeptide, or the carrier peptide. Oligopeptide is meant to include from 2 amino acids to 70 amino acids. Further, at times the invention is described as being an active agent attached to an amino acid, a dipeptide, a tripeptide, an oligopeptide, or polypeptide to illustrate specific embodiments for the active agent conjugate. Preferred lengths of the conjugates and other preferred embodiments are described herein. In another embodiment the number of amino acids is selected from 1, 2, 3, 4, 5, 6, or 7 amino acids. In another embodiment of the invention the molecular weight of the carrier portion of the conjugate is below about 2,500, more preferably below about 1,000 and most preferably below about 500.
Terms defined
[034] Controlled substance - a substance subject to federal regulation of its manufacture, sale, or distribution because of the potential for, or proved evidence of, abuse; because of its potential for psychic or physiological dependence; because it constitutes a public health risk; because of the scientific evidence of its pharmacologic effect; or because of its role as a precursor of other controlled substances. [035] Chemical moiety - a substance made up of chemical elements and characterized by a defined molecular composition. It can exist as a part of the drag conjugate and can be separated from the conjugate. Examples include an amino acid, an oligopeptide or a polypeptide, but may be any number of other substances.
[036] Although the discussion which follows focuses on oral administration of the controlled substance, it will be appreciated that the compositions and methods of the present invention are likewise applicable to injectable administration of the controlled substance.
[037] Covalent attachment of a chemical moiety to a controlled substance can render the substance pharmacologically inactive and resistant to absorption. Removal of the chemical moiety by enzymatic or chemical means, however, can restore the activity and the ability to be absorbed. The acidic conditions of the stomach and/or the enzymatic activity present in the gastrointestinal tract can therefore affect release of the active controlled substance. Provided release does not occur too rapidly, the pharmacologically active agent will be absorbed into the bloodstream by a time-release mechanism following oral administration. [038] One aim of the invention is to decrease potential for abuse by establishing oral extended release via covalent modification. Although this would theoretically decrease the potential for abuse, ideally it would probably only decrease the potential by approximately half for oral administration. For example, equal AUC with a blunted curve (Cmax - 50%) would only decrease the oral abuse potential by half (i.e. two anti-abuse pills would presumably induce approximately the same euphoric effect as one control pill). The DEA reports that abuse started with oral administration ultimately leads to intranasal or intravenous abuse due to tolerance. Once tolerance is established the rush effect sought requires the intranasal or intravenous route.
[039] When abused, controlled substances are typically delivered by means other than the oral route, namely by: i) parenteral injection; ii) intranasal delivery; or iii) inhalation. Administration by these routes results in rapid absorption into the bloodstream and the subsequent "rush" effect sought by the addict. It follows that an opoid conjugate that produces a significantly diminished euphoric effect when given by IN or IN, as compared in relative terms to its analgesic effect by oral administration, is valuable in diminishing its potential for abuse. Thus when given by these routes, the covalently modified compound of the invention (adopted for breakdown in the stomach or intestinal tract) is: i) not exposed to the necessary chemical and/or enzymatic conditions necessary for release of the active agent; or ii) the required activity is not present in sufficient amounts to affect rapid release/absorption. The covalently modified controlled substance, therefore, does not produce the euphoric effect sought by addicts.
[040] While other aspects of the invention, eg. sustained release etc. provide additional benefits to patients a preferred aspect of the invention is the design of an opoid conjugate product that has a reasonable shelf life (shelf safe) which can not be abused through current practices. It is a preferred embodiment of the invention, however, that the opoid conjugate not release the opoid through chemical action prior to administration.
[041] There are a number of mechanisms by which the potential for abuse of an analgesic may be decreased, including:
1. Decrease efficiency of the drugs ability to cross the LΝ barrier.
2. Decrease efficiency of the drugs ability to cross the blood brain barrier. note: 1 and 2 are likely correlated.
3. Increase in the half-life of a conjugate once it reaches the CSF (provided the conjugate is still effective as an analgesic. note: requires the drug-conjugate reaching the CSF.
4. Decreased conversion of the opoid conjugate to a more active metaboloite (e.g. codeine to morphine conversion).
In the case of opoids it may not be necessary (or even desirable) to have all drug release occur in the intestine. If some, or all, of the drug enters as a conjugate it is still a valuable therapeutic agent provided it can still reach the CSF and has an analgesic effect. In this regard "extended release" (more accurately extended analgesia) may be achieved post absorption. This might be accomplished by: 1) extended serum half-life 2) extended CSF half-life 3) temporal absorption across the blood brain barrier (provided it is eventually converted to parent drug and does not have an adverse effect of its own).
[042] The invention may be comprised of any controlled substance covalently attached to any chemical moiety, such as narcotics. Preferably, the controlled substance is an analgesic or stimulant. Further, the controlled substance is preferably of the group of analgesics comprised of the following: codeine, fentanyl, hydrocodone, hydromorphone, levorphanol, methadone, oxymorphone, morphine, oxycodone, propoxyphene, and sufentanyl. The controlled substance may also be amphetamine or methylphenidate. Examples of other controlled drugs include barbiturates, benzodiazepines, skeletal muscle relaxants e.g. meprobamate, and stimulants including amphetamine, methamphetamine, methylphenidate, pemoline, etc.
[043] In a preferred embodiment the invention provides a carrier and active agent which are bound to each other but otherwise unmodified in structure. This embodiment may further be described as the carrier having a free carboxy and/or amine terminal and/or side chain groups other than the location of attachment for the active agent. In a more preferred embodiment the carrier, whether a single -unino acid, dipeptide, tripeptide, oligopeptide or polypeptide is comprised only naturally occurring amino acids.
[044] The chemical moiety comprising the invention may be any chemical substance that can be attached to the controlled substance in a manner that renders it pharmacologically inactive. Analgesics and stimulants produce their pharmacological effects through binding to specific receptors or uptake proteins. The attachment of certain chemical moieties can therefore prevent the active substance from binding its receptor(s) or recognition site on its uptake protein. Further, without being bound by theory, the covalent modification is believed to prevent the pharmacological effect by preventing the drug from crossing the blood- brain barrier. Preferably, the attachment of the chemical moiety to the controlled substance will also prevent or substantially delay the absorption of the compound, particularly when the compound is delivered by routes other than oral administration. [045] Preferably, the attached chemical moiety is an amino acid or more preferably an oligopeptide. The oligopeptide preferably comprises less than 50 amino acids and more preferably less than 6 amino acids. The oligopeptide may comprise (i) a homopolymer of one of the twenty naturally occurring amino acids, (ii) a heteropolymer of two or more naturally occurring amino acids, (iii) a homopolymer of synthetic amino acids or (iv) a heteropolymer of two or more synthetic amino acids or (v) a heteropolymer of one or more naturally occurring amino acids and one or more synthetic amino acids.
[046] The attached chemical moiety may be comprised of other naturally occurring or synthetic substances. Controlled substances, for example, could also be attached to lipids, carbohydrates, nucleic acids, or vitamins. These chemical moieties could be expected to serve the same functions as a polypeptide; namely, effect delayed release in the gastrointestinal tract and prevent rapid absorption of the active agent.
[047] In one embodiment, the covalently attached chemical moiety is removed by the acidic content of the stomach if the controlled substance is attached through an acid labile bond. More preferably, the covalently attached chemical moiety can be removed by enzymatic activity encountered by the compound in the stomach and/or intestinal tract. The stomach and intestinal tract are bathed in degradative enzymes. For example, the pancreas releases into the small intestine a myriad of hydrolytic enzymes such as proteases, upases, and amylases, and nucleases. Additionally, the intestinal epithelial cells that line the surface of the GI tract produce various surface associated and intracellular degradative enzymes (e.g. brush border peptidases, esterases). These enzymes degrade proteins, lipids, carbohydrates, and nucleic acids contained in ingested food. Thus, it can be expected that the controlled substance will be released from the attached chemical moiety when the appropriate enzyme(s) is encountered in the gastrointestinal tract. [048] In another embodiment of the invention, the chemical moiety is attached to the controlled substance in a manner in which it is not readily released by conditions found in the mouth (saliva), the intranasal cavity, the surface of the lungs, or in the serum. Extreme acid conditions encountered in the stomach are not present elsewhere in humans. Therefore, any acid dependent release mechanism will occur only after oral administration. Although, degradative enzymes are present in the aforementioned environments, they are not generally present in the high concentrations found in the intestinal tract. Thus, release of the controlled substance by enzymatic cleavage will not occur rapidly when the novel compounds are administered by routes other than oral delivery.
[049] In another embodiment of the invention, the analgesic (e.g. oxycodone or hydrocodone) is attached to a polymer of serine (or other amino acid containing a hydroxyl side chain e.g. threonine, tyrosine) via side chain hydroxyl groups. Alternatively, attachment is to a polymer of glutamic acid through the carboxyl group of the delta carbon of glutamic acid. The resulting ester (carbonate) linkages can be hydrolysed by lipases (esterases) encountered in the small intestine. Esterases are not present at high levels in saliva or on the mucosal surfaces of the nasal cavity, lungs, or oral cavity. Thus, controlled substances attached to polyglutamic acid by this method would not be rapidly released by saliva or when delivered intranasally or by inhalation.
[050] In another embodiment of the invention, the analgesic is attached to an oligopeptide, preferably consisting of between one and five amino acids. In a further embodiment of the invention the amino acids are a heterogenous mixture of the twenty naturally occurring amino acids. Hydrophilic amino acids will tend to prevent passive absorption of the analgesic peptide conjugate through nasal membranes. Thus it is a preferred embodiment of the invention that hydrophilic amino acids be included in the oligopeptide. It is a further preferred embodiment of the invention that lipophilic amino acids be attached closer to the analgesic for optimum stability. Both lipophilic and hydrophilic properties (i.e., amphiphilic) can be satisfied with between three and five amino acids. Thus it is a more preferred embodiment of the invention that the oligopeptide that is attached to the analgesic be an amphiphilic tripeptide.
[051] Preferred amphiphilic amino acids/oligopeptides may be selected from (i) hydrophobic amino acids, preferably in positions next to the active agent to provide increased stability; (ii) amino acid sequences designed to be cleaved by intestinal enzymes (e.g. pepsin, trypsin, chymotrypsin, elastase, carboxypeptidases A and B, etc.) provide for increased bioavailability; (iii) peptides longer than three amino acids for increased stability, increased anti-abuse e.g. less membrane permeability, and potentially more efficient intestinal digestion e.g. major intestinal enzymes target proteins and polypeptides, (iv) or mixtures thereof. In one preferred embodiment the carrier portion of the conjugate is designed for intestinal cleavage. [052] In a preferred embodiment the cleavage specificity is directed to pepsin and/or chymotrypsin. Examples of preferred carriers include XXXAA or XXAAA, where X is selected from any amino acid, except Arg, Lys, His, Pro, and Met and A is selected from Tyr, Phe, Tip, or Leu. Examples of more preferred carriers are selected from XXXPheLeu wherein X is Glu; XXXPheLeu wherein X is Gly; XXPheLeuLeu wherein X is Glu; and XXPheLeuLeu wherein X is Gly. [053] In another embodiment the cleavage specificity is directed to trypsin.
Examples of preferred carriers include XXXAA or XXAAA wherein X is any amino acid except Pro and Cys and A is Arg or Lys. Examples of more preferred carriers are selected from XXXArgLeu wherein X is Glu; XXXArgLeu wherein X is Gly; XXArgLeuLeu wherein X is Gly; XXXArgLeuLeu wherein X is Gly. [054] The present invention provides covalent attachment of active agents to a peptide. The invention may be distinguished from the above mentioned technologies by virtue of covalently attaching the active agent directly, which includes, for example, pharmaceutical drugs and nutrients, to the N-terminus, the C- terminus or to the side chain of an amino acid, an oligopeptide or a polypeptide, also referred to herein as a carrier peptide.
[055] In another embodiment, the invention provides a composition comprising a peptide and an active agent covalently attached to the peptide. Preferably, the peptide is (i) an oligopeptide, (ii) a homopolymer of one of the twenty naturally occurring amino acids (L or D isomers), or an isomer, analogue, or derivative thereof, (iii) a heteropolymer of two or more naturally occurring amino acids (L or D isomers), or an isomer, analogue, or derivative thereof, (iv) a homopolymer of a synthetic amino acid, (v) a heteropolymer of two or more synthetic amino acids or (vi) a heteropolymer of one or more naturally occurring amino acids and one or more synthetic amino acids.
[056] The invention provides compositions comprising a carrier peptide and an active agent covalently attached to the carrier peptide. Preferably, the carrier peptide is (i) an amino acid, (ii) a dipeptide, (iii) a tripeptide, (iv) an oligopeptide, or (v) polypeptide. The carrier peptide may also be (i) a homopolymer of a naturally occurring amino acids, (ii) a heteropolymer of two or more naturally occurring amino acids, (iii) a homopolymer of a synthetic amino acid, (iv) a heteropolymer of two or more synthetic amino acids, or (v) a heteropolymer of one or more naturally occurring amino acids and one or more synthetic amino acids. [057] In another embodiment, the invention further provides a composition comprising a single amino acid, a dipeptide or a tripeptide with an active agent covalently attached. Preferably, the amino acid, dipeptide or tripeptide are (i) one of the twenty naturally occurring amino acids (L or D isomers), or an isomer, analogue, or derivative thereof, (ii) two or more naturally occurring amino acids (L or D isomers), or an isomer, analogue, or derivative thereof, (iii) a synthetic amino acid, (iv) two or more synthetic amino acids or (v) one or more naturally occurring amino acids and one or more synthetic amino acids. In another embodiment the amino acids are selected from L-amino acids for digestion by proteases. [058] In another embodiment, the peptide carrier can be prepared using conventional techniques. A preferred technique is copolymerization of mixtures of amino acid N-carboxyanhydrides. In another embodiment, the peptide can be prepared through a fermentation process of recombinant microorganisms followed by harvesting and purification of the appropriate peptide. Alternatively, if a specific sequence of amino acids is desired, an automated peptide synthesizer can be used to produce a peptide with specific physicochemical properties for specific performance characteristics.
[059] In another embodiment, direct attachment of an active agent to the carrier peptide may not form a stable compound therefore the incorporation of a linker between the active agent and the peptide is required. The linker should have a functional pendant group, such as a carboxylate, an alcohol, thiol, oxime, hydraxone, hydrazide, or an amine group, to covalently attach to the carrier peptide. [060] In another embodiment, the invention also provides a method for delivering an active agent to a patient, the patient being a human or a non-human animal, comprising administering to the patient a composition comprising a peptide and an active agent covalently attached to the peptide. In a preferred embodiment, the active agent is released from the composition by enzyme catalysis. In another preferred embodiment, the active agent is released in a time-dependent manner based on the pharmacokinetics of the enzyme-catalyzed release. [061] In another preferred embodiment, the active agent conjugates can incorporate adjuvants such that the compositions are designed to interact with specific receptors so that targeted delivery may be achieved. These compositions provide targeted delivery in all regions of the gut and at specific sites along the intestinal wall. In another preferred embodiment, the active agent is released as the reference active agent from the peptide conjugate prior to entry into a target cell. In another preferred embodiment, the specific amino acid sequences used are not targeted to specific cell receptors or designed for recognition by a specific genetic sequence. In a more preferred embodiment, the peptide carrier is designed for recognition and/or is not recognized by tumor promoting cells. [062] In another preferred embodiment, the active agent delivery system does not require that the active agent be released within a specific cell or intracellularly. In a preferred embodiment the carrier and/or the conjugate do result is specific recognition in the body. (e.g. by a cancer cell, by primers, for improving chemotactic activity, by sequence for a specific binding cite for serum proteins(e.g. kinins or eicosanoids).
[063] In another embodiment the active agent may be attached to an adjuvant recognized and taken up by an active transporter. In a more preferred example the active transporter is not the bile acid active transporter. In another embodiment, the present invention does not require the attachment of the active agent to an adjuvant recognized and taken up by an active transporter for delivery. [064] In a preferred embodiments the active agent conjugate is not bound to an immobilized carrier, rather it is designed for transport and transition through the digestive system.
[065] While microsphere/capsules may be used in combination with the compositions of the invention, the compositions are preferably not incorporated with microspheres/capsules and do not require further additives to improve sustained release.
[066] In a preferred embodiment the active agent is not a hormone, glutamine, methotrexate, daunorabicin, a trypsin-kallikrein inhibitor, insulin, calmodulin, calcitonin, L-dopa, interleukins, gonadoliberin, norethindrone, tolmetin, valacyclovir, taxol, or silver sulfadiazine. In a preferred embodiment wherein the active agent is a peptidic active agent it is preferred the active agent is unmodified
(e.g. the amino acid structure is not substituted).
[067] In a preferred embodiment the invention provides a carrier and active agent which are bound to each other but otherwise unmodified in structure. In a more preferred embodiment the carrier, whether a single amino acid, dipeptide, tripeptide, oligopeptide or polypeptide is comprises only naturally occurring amino acids.
[068] In a preferred embodiment the carrier is not a protein transporter (e.g. histone, insulin, transferrin, IGF, albumin or prolactin), Ala, Gly, Phe-Gly, or Phe-
Phe. In a preferred embodiment the carrier is also preferably not a amino acid copolymerized with a non-amino acid substitute such as PNP, a poly(alkylene oxide) amino acid copolymer, or an alkyloxycarbonyl (polyaspartate/polyglutamate) or an aryloxycarbonylmethyl (polyaspartate/polyglutamate).
[069] In a preferred embodiment neither the carrier or the conjugate are used for assay purification, binding studies or enzyme analysis.
[070] In another embodiment, the carrier peptide allows for multiple active agents to be attached. The conjugates provide the added benefit of allowing multiple attachments not only of active agents, but of active agents in combination with other active agents, or other modified molecules which can further modify delivery, enhance release, targeted delivery, and/or enhance adsorption. In a further embodiment, the conjugates may also be combined with adjuvants or be microencapsulated.
[071] In another preferred embodiment, the composition of the invention is in the form of an ingestible tablet or capsule, an intravenous preparation, an intramuscular preparation, a subcutaneous preparation, a depot implant, a transdermal preparation, an oral suspension, a sublingual preparation, an intranasal preparation, inhalers, or anal suppositories. In another embodiment, the peptide is capable of releasing the active agent from the composition in a pH-dependent manner. In another preferred embodiment the active agent is prepared and/or administered through means other than implantation and/or injectables. [072] Embodiments of the present invention preferably are not bound to an adjuvant recognized and/or taken up by active transporters. Preferably, the active agent conjugates of the present invention are not attached to active transporters, or antigenic agents such as receptor recognizing sequences found on cells and tumors. Preferably, the active agent conjugate of the present invention is not connected to or constitutes an implantable polymer, which would not biodegrade in less than 48 hours, preferably between 12 and 24 hours. The active agent conjugates of the present invention are preferably designed to release the active agent into the blood, after absorption from the gut, as the reference active agent.
[073] One embodiment of the invention relates to long acting narcotic drugs having significantly reduced abuse potential. The active agent is covalently bound to a peptide/oligopeptide or amino acid, which renders the active agent pharmaceutically inactive until released. Preferably the release mechanism is enzymatic action. Following oral administration the intestinal enzymes release the drug. The enzymatic and/or chemical conditions necessary for the release of the controlled substances is either not present or is minimally active when the drug- peptide conjugate is introduced by inhalation or injection. Thus it is expected that no euphoric effect will occur when the drug-peptide conjugate is inhaled or injected. Further, extending the release of the narcotic prevents spiking of drug levels which provide the desired analgesic effect with a lower or absent euphoria. Controlled substances with these novel properties are less likely to be abused due to the diminished "rush" effect of the modified controlled substance. Consequently, decreasing euphoria while increasing the duration of the analgesic effect enhances and reducing the likelihood of abuse increases the therapeutic value of these pharmaceuticals. The invention also provides for reproducible methods for compositions which are abuse-free for controlled substances, stable under a variety of chemical conditions, reduced euphoric effect and extended absorption into the bloodstream.
[074] The following examples are given by way of illustration and in no way should be construed as limiting as to the full scope of the invention.
EXAMPLES
Example 1: Naltrexone
[075] Naltrexone, an opoid antagonist, was chosen as a model compound for testing conjugates for the hypothesis that conjugates of opoid drugs can afford extended release, while also lowering the potential for abuse. Naltrexone is chemically similar to orally delivered analgesics such as oxycodone and hydromorphone and therefore amenable to synthesizing conjugates for testing in vitro and in vivo performance. Synthesis
[076] Polyserine-naltrexone (carbonate-linked) conjugates were synthesized by the following method:
1) Polymer activation. N-acetylated polyserine-methyl ester (0.69 g, 7.9 rnmol) was dissolved in N-methylpyrolidinone (15 ml) and allowed to stir under argon at ambient temperature. Carbonyldiimmidazole (GDI, 1.93g, 11.9mmol) was added and the reaction allowed to stir over night under argon. Then, 100 ml of acetonitrile were added and the mixture allowed to sit at 4 °C for 2 hours. The precipitate that formed was collected by centrifugation and the resulting pellet then resuspended in acetonitrile. This suspension was then centrifuged and the pellet dried over night under a vacuum. 2) Tetrabutylammonium salt of naltrexone. Naltrexone hydrochloride (1.5g, 3.979mmol) was dissolved in water (~50ml) and this solution titrated with IN LiOH to a pH of -11-12. Tetrabutylammonium chloride (2.6g, 4.0mmol) was then added. The aqueous solution was then extracted with 3 equal volumes of chloroform (20ml each). The organic solutions were pooled and dried with magnesium sulfate. The solvent was then removed using a rotovap, and the resulting solid dried over night under a high vacuum.
3) Conjugation reaction. The solid material from step 1 was dissolved/suspended in 15 ml of N-methylpyrrolidinone and the resulting solution placed under argon. The naltrexone salt from step 2 was then added, and the reaction then allowed to warm to -50-60 °C. The reaction was then allowed to stir two days under these conditions, at which point water was added (-200 ml). The aqueous solution was then concentrated by ultrafiltration (1000 mw cutoff). The concentrated solution (-5 ml) was then diluted to a volume of 50 ml with water. The aqueous solution was then titrated to pH 3 with IN HC1 and then concentrated by ultrafiltration. This process was repeated two more times. Following the final concentration, the aqueous solution (~5ml) was then freed of solvent using a rotovap and high vacuum. The resulting solid was then stored over night under high vacuum. This afforded 50 mg of brown solid. A serine altrexone ratio of approximately 1:6 (BB272) and 1:10 (BB301) was estimated by nuclear magnetic resonance (NMR). A schematic of synthesis is shown in Fig. 1.
Example 2; In vivo performance of polyserine-naltrexone conjugate (rat model)
[077] Polyserine-naltrexone conjugates were tested in Sprague-dawley rats
(~ 250 g). Defined doses were delivered orally in gelatin capsules containing purified dry powder polyserine-naltrexone conjugates or naltrexone. No excipients were added to the capsules.
[078] Content of naltrexone in the polyserine-naltrexone conjugate BB272 was estimated to be 30% as based on the 1:6 ratio of naltrexone:serine determined by NMR. Polyserine-naltrexone conjugate was given to four rats at a dose of 12 mg which contained 3.6 mg of naltrexone. Doses of naltrexone (3.6 mg) equivalent to the naltrexone content of the conjugate were also given to four rats. Capsules were delivered orally to rats at time-zero using a capsule dosing syringe. Seram was collected from rats 2, 4, 6, 9, and 12 hours after capsule delivery. Seram naltrexone concentrations were determined by ELISA using a commercially available kit (Nalbuphine, product #102819, Neogen Corporation, Lansing MI).
Figure imgf000022_0001
[079] Serum levels of individual animals are shown in Table 1. Mean serum levels are shown in Table 3. (Example 2). As shown in Fig. 2, serum levels spiked earlier for naltrexone (2 hours) than for the drug administered as a polyserine-naltrexone conjugate (4 hours). Serum levels of naltrexone for the polyserine-naltrexone conjugate remained elevated considerably longer than for naltrexone. Additionally, the peak level was significantly lower for the polyserine- naltrexone conjugate. It should be noted that the 2 hour time point was the first measurement of naltrexone seram levels. Since this was the peak level measured for naltexone it can not be determined whether or not levels peaked at a higher concentration earlier. Consequently, it was not possible to accurately determine the Cmax or area under serum concentration curve (AUC) for naltrexone in this experiment. Example 3: In vivo performance of polyserine-naltrexone conjugate
[080] Polyserine-naltrexone conjugates were tested in Sprague-dawley rats
(~ 250 g). Defined doses were delivered orally in gelatin capsules containing purified dry powder polyserine-naltrexone conjugates or naltrexone. No excipients were added to the capsules.
[081] Content of naltrexone in the polyserine-naltrexone conjugate BB272 was estimated to be 30% as based on the 1:6 ratio of naltrexone :serine determined by NMR. Polyserine-naltrexone conjugate was given to five rats at a dose of 12.9 mg which contained 3.6 mg of naltrexone. Doses equivalent to the naltrexone contained in the batch of polyserine-naltrexone (BB 301) were also given to five rats. Additionally, half the equivalent dose (1.8 mg) was given at time-zero, followed by a second half-dose at 6.5 hours to five rats.
[082] Capsules were delivered orally to rats at time-zero using a capsule delivery syringe. Seram was collected at 0.5, 1.5, 3, 5, 8, 12, 15 and 24 hours after capsule delivery for the polyserine-naltrexone (BB301) and equivalent naltrexone dosed rats. Serum was collected at 0.5, 1.5, 3, 5, 8, 11.5, 14.5 and 24 hours after capsule delivery for rats dosed with half-equivalent doses at 0 and 6.5 hours. Seram naltrexone concentrations were determined by ELISA using a commercially available kit (Nalbuphine, product #102819, Neogen Corporation, Lansing MI).
Figure imgf000024_0001
Figure imgf000024_0002
[083] Seram levels of individual animals are shown in Table 2. Mean serum levels are shown in Table 3. As shown in Fig. 3, naltrexone serum levels spiked earlier (0.5 hours) for naltrexone than for the drag administed as a polyserine-naltexone conjugate (5 hours). Seram levels of naltrexone for the polyserine-naltrexone conjugate remained elevated considerably longer (> 12 hours) than for the monomeric naltrexone control (< 8 h). Seram concentration curves crossed at approximately 7 hours. Additionally, the mean of the peak level concentration (Cmax) was significantly lower for the conjugated naltrexone (Table 4). Further, the mean time to peak concentration (Tmax) was significantly longer for the polyserine-naltrexone conjugate (Table 4). The mean AUC of the polyserine- naltrexone conjugate was approximately 75% of the naltrexone mean AUC (Table 4). Statistically the mean AUCs were not significantly different (P< 0.05). Seram levels of rats fed one-half-dose (1.8 mg) at time zero and at 6.5 hours were compared to those of rats fed polyserine-naltrexone conjugate. Concentration levels remained elevated for the conjugate past those for the second naltrexone dose, with the curves crossing at approximately 2.5 hours and again at approximately 11 hours (double cross-over of the serum concentration curves).
Figure imgf000025_0001
Example 4: Synthesis of an Analog of Hydrocodone
[084] A synthesized analog of hydrocodone, the compound, 6-O- ethoxycarbonyl hydrocodone (EtOCOhydrocodone), was prepared by reaction of the enolate of hydrocodone with ethylchloroformate. The hydrocodone portion was not released under a wide range of pH's and temperatures. EtOCOhydrocodone was studied in a rat model and its pharmacokinetics was nearly identical to that of the reference drag (Figure 4). Ethoxycarbonylhydrocodone's AUC is 90% of hydrocodone' s AUC. EtOCOhydrocodone meets the criteria for an abuse-free narcotic (i.e., stability and in vivo release) when injected.
[085] Further, the C-terminus of glutamic acid, leucine, proline, lysine, serine and glycine where attached to the 6-O position of hydrocodone and the C- terminus of glutamic acid to the 6-0 position of oxycodone. Figure 5 shows a general scheme for how amino acid narcotic conjugates are synthesized using oxycodone and hydrocodone as examples. The anion of oxycodone (or hydrocodone) was reacted with the protected N-hydroxysuccinimide ester (OSu) of the respective amino acid, which is fully deprotected in HCl/dioxane to yield the final product. For example, the enolate of oxycodone is reacted with BocGlu(OtBu)OSu to yield 6-O-BocGlu(OtBu)-oxycodone, which when deprotected gives 6-O,α -glutamyloxycodone. This oxycodone derivative showed similar pharmacokinetics and had 20% greater AUC relative to the parent drug in a rat model. (Figure 6).
Example 5; Synthesis of Methylated Opoid Conjugates
Figure imgf000026_0001
Boc-Ser(CO-Methyl Naltrexone)-OtBu
[086] To a solution of methyl naltrexone (l.OOg, 2.82 mmol) in THF at -
78°C was added LiN(SiMe3)2 (1.0M in THF, 5.92 mmol) dropwise via syringe. This solution was stirred at -78°C for 1 hour. In a separate reaction, Boc-Ser-OtBu (0.220g, 0.84mmol) was dissolved in THF (5 ml) with NMM (0.10 ml, 0.92 mmol) and triphosgene (0.250 g, 0.84 mmol) added. This solution was stirred at -78°C for 30 minutes. The first reaction was added slowly to the second at -78°C. The combined reaction was allowed to warm to ambient temperature and stirred for 18 hours. After this, water (10 ml) was added. Solvent was removed and residue was partitioned between CHCl3/water (50 ml each) and was extracted twice with CHC13 (50 ml). Combined organics were washed with brine(50 ml), pH 8 water(50 ml), dried with MgSO4 and solvent removed. A preparative TLC was taken (100% CHC13). NMR of TLC material confirmed the presence of product. [087] The results of examples 1 through 3 show that conjugation of naltrexone to a polymer of serine via a carbonate linkage can prevent spiking of the drug (decrease Cmaχ) and afford sustained release (increase Tmax while maintaining approximately equal AUC). Further, example 4 shows that carbonate linked compounds are substantially resistant to release of naltrexone by exposure to acid, base and protease. Other opoid conjugates can be synthesized in a similar manner to obtain similar characteristics. Example 5 provides an additional method of synthesis by which opoid carbonate conjugates can be synthesized. In particular, this method allows for conjugation to oxycodone via a carbonate linkage. Example 6; Synthetic Protocol for Amino Acid Conjugate of (S)-amphetamine
[088] Synthesis of Protected Conjugate, Example = BOC-Glu(OtBu)-
SAMP The starting material for all these syntheses is dextroamphetamine sulfate which was obtained from Sigma/ Aldrich. Since the relative configuration denoted by the term "dextro" may not be relevant to the conjugates, the material is referred to here as the (S)-isomer. This absolute configuration does not change during the reaction sequences.
[089] To a solution of S-amphetamine sulfate (750 mg, 4.07 mmol) in 5 mL of anhydrous DMF stirring at room temperature in an oven-dried 50 mL flask under an Ar atmosphere was added 2.11 mL of diisopropylemylamine (DIPEA, 12.21 mmol). After 5 minutes, BOC-Glu(OtBu)-OSu (1.709 g, 4.07 mmol) in 10 mL of anhydrous EtOAc was added and the mixture was allowed to stir at room temperature overnight. The tic (9/1 CHCl /MeOH) indicates that the amphetamine starting material is gone since the UN-active spot on the baseline is no longer present.
Figure imgf000028_0001
[090] The reaction mixture was poured into 30 mL of EtOAc and washed with 2 X 50 mL of dilute HCl in water (pH 3) and 50 mL of saturated NaCl. After drying over MgSO , the solution was filtered and the solvent reduced by rotary evaporation. The residue was taken up in a minimum amount of methylene chloride and ran through a silica flash column eluting with 50/1 CH2Cl2/MeOH (adding progressively more MeOH) to 30/1 CH Cl2/MeOH. The fast running product was easily separated from the more polar components. After rotary evaporation of the solvent and drying overnight by high vacuum, the purified product (1.625 g, 95%) was ready for the next reaction. The NMR in CDC13 was consistent with the structure. [091] Synthesis of Deprotected Conjugate, Example = Glu-SAMP-HCl
[092] A mixture of BOC-Glu(OtBu)-SAMP (1.36 g, 3.23 mmol) and 10 mL of 4M HCl in dioxane was stirred at room temperature in an oven-dried flask under an Ar atmosphere overnight. At this time, the fast-moving protected intermediate was no longer visible on tic. The solvent was removed by rotary evaporation and the material was dried under high vacuum leaving 886 mg (91%) of the HCl salt. The nmr (dmso-d6) was consistent with the product.
4M HCI/dioxane
Figure imgf000028_0002
Figure imgf000028_0003
[093] Data from Rat Pharmakinetic Experiments Comparing Amphetamine with Peptide Conjugates
[094] Experiments involved male Sprague-Dawley rats (weight 250-300g) dosed at time zero by oral gavage with a solution of d-amphetamine sulfate (amphetamine) or an equimolar solution of one of the peptide conjugates. Serum samples were obtained by eye bleeds and concentrations determined by ELISA assays. (Figures 7 and 8).
Example 7; In Vivo Performance Of Amphetamine Conjugates
[095] Pharmacokinetcis by Oral Administration
Peptide-amphetamine conjugates and an equivalent amount of parent amphetamine contained in the conjugate were orally administered separately to male Sprague-Dawley rats (-250 g). Drugs were delivered as oral solutions in water. The amphetamine content of each conjugate was determined by NMR analysis. Serum levels of amphetamine were analyzed by ELISA (Neogene, Lexington, KY, Amphetamine kit. 109319).
[096] GluGlu-amphetamine and Phe-amphetamine had nearly equal Cmax and AUC to those of the parent drug (Table 5). The serum concentration curves are shown in Fig. 8. No change in the shape of the curve was observed for the amphetamine conjugates.
Table 5. Pharmacokinetic Parameters of Peptide- Amphetamine Conjugates
Figure imgf000029_0001
Example 8: In Vivo Performance Of Narcotics Conjugates
Pharmacokinetics by Oral Administration
[097] Peptide-narcotic conjugates and an equivalent amount of parent narcotic (hydrocodone or oxycodone) contained in the conjugate were orally administered separately to male Sprague-Dawley rats (-250 g). Drugs were delivered as oral solutions in water or phosphate buffered saline or as solids in gelatin capsules. The narcotic content of each conjugate was determined by HPLC analysis. Serum levels of hydrocodone and oxycodone were analyzed by ELISA (Neogene, Lexington, KY, Oxymorphone/Oxycodone kit. 102919 and Hydromorphone/Ηydrocodone kit. 106610-1).
Table 6. In Nivo Performance of Opoid Conjugates Administered Orally
Figure imgf000031_0001
Oral Bioequivalence
[098] Oral studies are summarized in Table 6. Seventeen narcotic conjugates have been tested for oral bioavailability vs. the parent drug. These include 13 peptide conjugates, 2 monosaccharide conjugates, and 2 lipid conjugates. Eleven of the nine peptide conjugates had 60% or greater bioavailability based on AUC. Examples, which when compared to an equivalent dose of the parent drug, include: Glu-Oxycodone which was 121% bioavailable (Fig. 6); GlyGlyLeu- Hydrocodone which was 82% bioavailable (Fig. 9), and GluGluGlu-HC which was 117% bioavailable (Fig. 10). The Ribose-HC conjugate had 106% when compared to an equivalent dose of the parent drag (Fig 11).
Oral Kinetics
[099] A sustained release profile was observed with one of the amino acid conjugates Glu-Oxycodone (Fig. 6). The compound showed a blunted curve (decrease in Cmax) combined with a 2- fold increase in time to peak concentration (Tmax) and approximately equivalent AUC. Glu-Oxycodone, however, is not sufficiently stable to warrant consideration as an anti-abuse product. No other narcotics compounds tested to date showed sustained release kinetics with equal AUC. One other compound, protected Glu-Leu-HC, showed an increase in Tmax without equal AUC.
Pharmacokinetcis by Intranasal Administration
Table 7. In Vivo Performance of Opoid Conjugates Administered Intranasally
Figure imgf000033_0001
Intranasal Bioavailability
[0100] Intranasal (IN) studies are summarized in Table 7. All peptide conjugates tested thus far had decreased absorption by the intranasal route. Preliminary data suggests that inhibition of absorption is correlated with 1) length of peptide, 2) polarity, and 3) charge. GluGlu-HC and GluGluGlu-HC were inhibited more than Glu-HC. A relatively lipophilic tripeptide GlyGlyLeu was not inhibited as much as the more polar tripeptide GluGluGlu-HC. GlupyroGlu-HC was absorbed more rapidly that GluGlu-HC, which has a greater net (negative) charge (Fig. 12). [0101] The IN absorption of Ribose-HC (Fig. 13) was significantly inhibited
(approximately 80%). This particular compound still contained small amounts of free hydrocodone; therefore, inhibition of absorption may have been essentially complete.
[0102] The IN model was used to test the absorption of EEE-HC in water and in saline (PBS, pH 7.4). The inhibition of IN absorption was more significantly inhibited in PBS than in water. Therefore other compounds should be tested in the IN model in water and perhaps other buffers.
Example 9; Stability of Narcotic Conjugates
[0103] It is also possible to further stabilize any unstable conjugates by tethering to a larger peptide. To illustrate this point, the synthetic precursors, 6-O-
BocGlu(OtBu)hydrocodone and 6-O-BocLys(NHBoc)-hydrocodone, which are completely stable in water at room temperature and under heated conditions as shown in Table 8 and Table 9. The conjugates are also stable at a wide range of pH's.
[0104] Table 8: Hydrolysis rate of Amino Acid/Narcotic conjugates in water
Figure imgf000034_0001
Figure imgf000034_0002
Figure imgf000035_0001
Figure imgf000036_0001
[0105] The protected amino acid-hydrocodone compounds were tested in a typical rat model. Biphasic absorption of hydrocodone in rat sera fed 6-O- BocGlu(OtBu)-hydrocodone and 6-O-BocLys(NHBoc)hydrocodone was observed (Figure 14). The AUCs for both amino acid/hydrocodone conjugates are 75% of hydrocodone' s AUC.
[0106] The stability of the amino acid/narcotic conjugates can be increased by tethering it to a larger peptide via the nitrogen on the amino acid residue. This will also extend the absorption of the orally administered drag. For instance, the dipeptides added to hydrocodone include GluGlu, LeuGlu, AlaPro, GluPro and GluLeu.
Example 10: Preparation of Ala-Pro-Hydrocodone
Boc-Ala-OSu 4N HCl in dioxane ., „ ., . Pro-Hydrocodone *- Boc-Ala-Pro-Hydrocodone »- Ala-Pro-Hydrocodone
Figure imgf000036_0002
Ala-Pro-Hydrocodone
[0107] To a solution of Pro-Hydrocodone in DMF was added NMM followed by Boc-Ala-OSu. The solution was stirred at ambient temperatures for 18hours. Solvent was removed. Crude material was purified using preparative HPLC (Phenomenex Luna C18, 30X250mm, 5μM, lOOA; Gradient: 100 water/0 0.1% TFA-MeCN -» 0/100; 30ml/min.). Solid was collected as a slightly yellow powder (0.307g, 85% yield): 1H NMR (DMSO-d6) 5 1.16 (d, 3H), 1.35 (s, 9H), 1.51 (m, 2H), 1.86-2.10 (m, 6H), 2.50 (m, 1H), 2.54 (m, 1H), 2.69 (m, 1H), 2.88 (s, 3H), 3.02 (dd, 1H), 3.26 (d, 1H), 3.55 (m, 1H), 3.67 (m, 1H), 3.72 (s, 3H), 3.80 (s, 1H), 4.25 (m, 1H), 4.43 (d, 1H), 5.01 (s, 1H), 5.59 (d, 1H), 6.75 (d, 1H), 6.88 (d, 1H), 6.99 (t, 1H), 9.91 (br s, 1H).
[0108] To the Boc-Ala-Pro-Hydrocodone (O.lOOg) was added 10ml of 4N
HCl in dioxane. The resulting mixture was stirred at ambient temperatures for 18 hours. Solvent was removed and final product dried under vacuum. Solid was collected as a slightly yellow solid (0.56g, 71% yield): 1H NMR (DMSO-d6) 6 1.38 (s, 3H), 1.48 (t, 1H), 1.80-2.29 (m, 8H), 2.65 (m, 1H), 2.80 (s, 3H), 2.96 (m, 3H), 3.23 (m, 2H), 3.76 (s, 3H), 3.92 (s,lH), 4.22 (s, 1H), 4.53 (s, 1H), 5.00 (s, 1H), 5.84 (d, 1H), 6.77 (d, 1H), 6.86 (d, 1H), 8.25 (br s, 3H). Example 11: Preparation of Gly-Gly-GIy-Gly-Leu-Hydrocodone
Boc-Glv-Gly-OSu Gly-Gly-Leu-Hydrocodone - — - *- Boc-Gly-Gly-Gly-Gly-Leu-Hydrocodone
4N HCl in dioxane Gly-Gly-Gly-Gly-Leu-Hydrocodone
Figure imgf000037_0001
Gly-Gly-Gly-Gly-Leu-Hydrocodone
[0109] To a solution of Gly-Gly-Leu-Hydrocodone in DMF was added
NMM followed by Boc-Gly-Gly-OSu. The solution was stirred at ambient temperatures for lδhours. Solvent was removed. Crude material was purified using preparative HPLC (Phenomenex Luna C18, 30X250mm, 5μM, 100A; Gradient: 85 water/15 0.1% TFA-MeCN -> 50/50; 30ml/min.). Solid was collected as a slightly yellow powder (0.304g, 37% yield).
[0110] To the Boc-Gly-Gly-Gly-Gly-Leu-Hydrocodone (0.304g) was added
25ml of 4N HCl in dioxane. The resulting mixture was stirred at ambient temperatures for 18 hours. Solvent was removed and final product dried under vacuum. Solid was collected as a slightly yellow solid (0.247g, 97% yield): 1H NMR (DMSO-d6) 6 0.87 (m, 6H), 1.23 (s, 1H), 1.51-1.86 (m, 4H), 2.18 (m, 1H), 2.71 (m, 2H), 2.77 (s, 3H), 2.96 (m, 2H), 3.17 (m, 2H), 3.61 (s, 3H), 3.81-3.84 (m, 10H), 4.22 (m, 1H), 4.36 (m, 1H), 5.09 (m, 1H), 5.59 (d, 1H), 6.74 (dd, 2H), 8.16 (br s, 4H), 8.38 (br s, 1H), 8.74 (br s, 1H), 11.42 (br s, 1H). Example 12: Preparation of Gly-Gly-Leu-Hydrocodone
Boc-Gly-Gly-OSu 4N HCl in dioxane Leu-Hydrocodone — »- Boc-Gly-Gly-Leu-Hydrocodone *- Gly-Gly-Leu-Hydrocodone
Figure imgf000038_0001
Gly-Gly-Leu-Hydrocodone
[0111] To a solution of Leu-Hydrocodone in DMF was added NMM followed by Boc-Gly-Gly-OSu. The solution was stirred at ambient temperatures for lδhours. Solvent was removed. Crude material was purified using preparative HPLC (Phenomenex Luna C18, 30X250mm, 5μM, lOOA; Gradient: 90 water/10 0.1% TFA-MeCN ■ 0/100; 30ml/min.). Solid was collected as a slightly yellow powder (2.08g, 73% yield): 1H NMR (DMSO-d6) δ 0.88 (dd, 6H), 1.38 (s, 9H), 1.53-1.72 (m, 5H), 1.89 (d, 1H), 2.15 (m, 1H), 2.67 (m, 2H), 2.94 (s, 3H), 3.05 (m, 2H), 3.25 (m, 2H), 3.56 (d, 3H), 3.76 (s, 6H), 3.98 (s, 1H), 4.35 (q, 1H), 5.04 (s, 1H), 5.59 (d, 1H), 6.77 (d, 1H), 6.85 (d, 1H), 7.04 (t, 1H), 8.01 (t, 1H), 8.30 (d, 1H), 9.99 (br s, 1H).
[0112] To the Boc-Gly-Gly-Leu-Hydrocodone (2.08g) was added 50ml of
4N HCl in dioxane. The resulting mixture was stirred at ambient temperatures for 18 hours. Solvent was removed and final product dried under vacuum. Solid was collected as a slightly yellow solid (1.72g, 86% yield): 1H NMR (DMSO-d6) δ 0.89 (dd, 6H), 1.50-1.87 (m, 5H), 2.26 (m, 2H), 2.66 (m, 2H), 2.82-2.97 (m, 5H), 3.21 (m, 2H), 3.60 (m, 4H), 3.88 (m, 5H), 4.37 (m, 1H), 5.04 (s, 1H), 5.60 (s, 1H), 6.79 (d, 2H), 8.07 (br s, 3H), 8.54 (br s, 1H), 8.66 (br s, 1H), 11.29 (br s, 1H). Example 13: Preparation of Leu-Hydrocodone
1. LiN(TMS)2, THF 4N HCl in dioxane
Hydrocodone >■- Boc-Leu-Hydrocodone *- Leu-Hydrocodone
2. Boc-Leu-OSu
Figure imgf000039_0001
Leu-Hydrocodone
[100] To a solution of hydrocodone in THF was added LiN(TMS)2 in THF via syringe. The solution was stirred at ambient temperatures for 5 minutes then Boc-Leu-OSu was added. The resulting reaction mixture was stirred at ambient temperatures for 18 hours. Reaction was neutralized to pH 7 with 6M HCl. Solvent was removed. Crude material was taken up in CHC13 (100ml), washed with sat. NaHCO3 (3X100ml), dried over MgSO4, filtered, and solvent removed. Solid was collected as a yellow powder (1.98g, 95% yield): 1H NMR (DMSO-d6) δ 0.86 (dd, 6H), 1.31 (s, 9H), 1.46 (s, 2H), 1.55 (m, 2H), 1.69 (m, IH), 1.87 (dt, IH), 2.07 (dt, 2H), 2.29 (s, 3H), 2.43 (m, 2H), 2.93 (d, IH), 3.11 (s, IH), 3.72 (s, 3H), 3.88 (dt, IH), 4.03 (dt, IH), 4.87 (s, IH), 5.51 (d, IH), 6.65 (d, IH), 6.73 (d, IH), 6.90 (s, IH).
[101] To the Boc-Leu-Hydrocodone was added 25ml of 4N HCl in dioxane. The resulting mixture was stirred at ambient temperatures for 18 hours. Solvent was removed and final product dried under vacuum. Solid was collected as a slightly yellow solid (1.96g, 97% yield): 1H NMR (DMSO-d6) δ 0.94 (d, 6H), 1.52 (m, IH), 1.75-1.90 (m, 4H), 2.22 (dt, IH), 2.34 (dt, IH), 2.64 (q, IH), 2.75 (s, 3H), 2.95-3.23 (m, 4H), 3.74 (s, 3H), 3.91 (d, IH), 4.07 (s, IH), 5.10 (s, IH), 5.72 (d, IH), 6.76 (d, IH), 6.86 (d, IH), 8.73 br s, 3H).
Example 14: Analgesia of GlvGlvGlu-HC and ProProLeu-HC vs. HC Subcutaneously Injected
[102] Peptide-narcotic conjugates GlyGlyGlu-HC and ProProLeu-HC and an equivalent amount of HC contained in the conjugates were subcutaneously administered separately to male Sprague-Dawley rats (-250 g). The level of analgesia was scored by the PLL (paw lick latency) method using the hot plate nociceptive model as described (Tomkins, D.M., et al. J Pharmacol Experimental Therapeutics, 1997, 280:1374-1382). Table 10 shows the latency response of GlyGlyGlu-HC vs. HC. Basal PLL times of untreated rats were subtracted from the conjugate and hydrocodone PLLs. At thirty minutes analgesia of GlyGlyGlu-HC was 54 % and at 45 minutes was 8 %, when PPLs above basal level were compared to HC indicating that analgesia was significantly inhibited by the attached tripeptide. The latency response of ProProLeu-HC vs. HC is shown in Fig. 15 and Table 11. PLL times above 0 hour basal level of pretreated rats is was scored at 15, 30, 45, and 60 minutes. At the thirty minute peak of analgesia ProProLeu-HC was 9 % of that for hydrocodone. The PPL latency score of ProProLeu-HC gradually rose over time, however, at 60 minutes was still only 43% of the hydrocodone. (note: a cutoff time of 45 seconds was used in the PLL scoring in order to minimaize any harm to the animals. Most of the hydrocodone treated animals reached the maximum 45 seconds at peak analgesia).
Table 10. Paw Lick Latency of GlyGlyGlu-HC vs. Hydrocodone
Figure imgf000041_0001
Table 11. Paw Lick Latency of ProProLeu-HC vs. Hydrocodone
Figure imgf000041_0002
[0113] The latency response of LeuLeuLeu-HC, ProProIle-HC,
GlyGlyGlyGlyLeu-HC, and GlyGlyGlyGly-HC (2X the equivalent dose) is shown in Table 12 and Fig. 16. PLL times above 0 hour basal level of pretreated rats was scored at 15, 30, and 60 minutes. At the thirty minute peak of analgesia
Figure imgf000042_0001
hydrocodone was the only test group that showed any response. The PPL latency scores of the peptide conjugates did not rise above the basal response, including the GlyGlyGlyGly-HC treated group that received twice the hydrocodone control dose.
Example 15: Active Agent List
[103] The active agent that is attached to the carrier peptide can have one or more of different functional groups. The functional groups include an amine, carboxylic acid, alcohol, ketone, amido (or its chemical equivalent), thiol or sulfate. Examples of these active agents, their functional groups and site of attachment to the carrier peptide is provided in the section below. One skilled in the art would recognize the techniques necessary to covalently attach a peptide to the active agents as described through the application.
Acetaminophen with Codeine
[104] Acetaminophen is a known pharmaceutical agent that is used in the treatment of minor aches and pains. Its chemical name is N-acetyl-p-aminophenol. It is often used in combination with codeine, whose chemical name is 7,8- didehydro-4,5-α-epoxy-3-methoxy- 17-methylmephorninan-6α-ol. Both are commercially available and readily manufactured using published synthetic schemes by those of ordinary skill in the art.
[105] In the present invention, both acetaminophen and codeine are covalently attached to the peptide via their hydroxyl groups.
Codeine
[106] Codeine is a known pharmaceutical agent that is used in the treatment of pain. The composition of the invention comprises codeine covalently attached to a peptide.
[107] In the present invention, codeine is covalently attached to the peptide via the hydroxyl group.
Dihydrocodeine
[108] Dihydrocodeine is a known pharmaceutical agent that is used in the treatment of pain. The composition of the invention comprises dihydrocodeine covalently attached to a peptide.
[109] In the present invention, dihydrocodeine is covalently attached to the peptide via the hydroxyl group.
Codeine and guaifenesin
[110] Codeine and guaifenesin is a known pharmaceutical agent that is used in the treatment of coughs. The composition of the invention comprises codeine and guaifenesin covalently attached to a peptide via the hydroxyls of either active agent.
Codeine and promethazine
[111] Codeine and promethazine are known pharmaceutical agents used in the treatment of coughs. The composition of the invention comprises codeine and promethazine covalently attached to a peptide via functional groups specified in the active agent's respective catagory. Codeine, guaifenesin and pseudoephidrine
[112] Codeine, guaifenesin and pseudoephidrine are used in the treatment of coughs and colds. The composition of the invention comprises codeine, guaifenesin and pseudoephidrine covalently attached to a peptide peptide via functional groups specified in the active agent's respective catagory.
Codeine, phenylephrine and promethazine
[113] Codeine, phenylephrine and promethazine is a known pharmaceutical agent that is used in the treatment of coughs and colds. The composition of the invention comprises codeine, phenylephrine and promethazine covalently attached to a peptide via functional groups specified in the active agent's respective catagory.
Fentanyl
[114] Fentanyl is a known pharmaceutical agent that is used in the treatment of pain. It is both commercially available and readily manufactured using published synthetic schemes by those of ordinary skill in the art. Its structure is:
Figure imgf000044_0001
[115] In the present invention, the fentanyl or modified fentanyl is covalently attached to the peptide via a linker. This linker may be a small molecule containing 2-6 carbons and one or more functional groups (such as amines, amides, alcohols, or acids) or may be made up of a short chain of either amino acids or carbohydrates.
Acetaminophen and hydrocodone
[116] Acetaminophen and hydrocodone is a known pharmaceutical agent that is used in the treatment of pain. The chemical name of acetaminophen is N- acetyl-p-aminophenol. The composition of the invention comprises acetaminophen and hydrocodone covalently attached to a peptide.
Chlorpheniramine and hydrocodone
[117] Chlorpheniramine and hydrocodone is a known pharmaceutical agent that is used in the treatment of pain. The composition of the invention comprises chlorpheniramine and hydrocodone covalently attached to a peptide.
Guaifenesin and hydrocodone
[118] Guaifenesin and hydrocodone is a known pharmaceutical agent that is used in the treatment of coughs. The composition of the invention comprises guaifenesin and hydrocodone covalently attached to a peptide using functional groups specifally described in the active agents respective category.
Himatropine and hydrocodone
[119] Himatropine and hydrocodone is a known pharmaceutical agent that is used in the treatment of pain. The composition of the invention comprises himatropine and hydrocodone covalently attached to a peptide using functional groups specifally described in the active agents respective category.
Hydrocodone and phenylpropanolamine
[120] Hydrocodone and phenylpropanolamine are used in the treatment of coughs and colds. The composition of the invention comprises hydrocodone and phenylpropanolamine covalently attached to a peptide.
[121] In the present invention, hydrocodone and phenylpropanolamine is covalently attached to the peptide via one of the hydroxyl groups. Alternatively, phenylpropanolamine can be covalently attached to the peptide via the amino group.
Ibuprofen and hydrocodone
[122] ibuprofen and hydrocodone are used in the treatment of pain. The structure of ibuprofen is:
Figure imgf000046_0001
The composition of the invention comprises ibuprofen and hydrocodone covalently attached to a peptide using functional groups specifically described in the active agents respective category.
Hydrocodone
[123] Hydrocodone is a known pharmaceutical agent that is used in the treatment of pain. The composition of the invention comprises hydrocodone covalently attached to a peptide.
[124] In the present invention, hydrocodone is covalently attached to the peptide via a ketone group and a linker. This linker may be a small linear or cyclic molecule containing 2-6 atoms with one or more heteroatoms and one or more functional groups (such as amines, amides, alcohols or acids). For example, glucose would be suitable as a linker. Alternatively, hydrocodone may be attached directly through an enolate.
Hydromorphone
[125] Hydromorphone is a known pharmaceutical agent that is used in the treatment of cough and pain. Its structure is:
Figure imgf000046_0002
[126] The composition of the invention comprises hydromorphone covalently attached to a peptide.
[127] In the present invention, hydromorphone is covalently attached to the peptide via the hydroxyl group. Morphine
[128] Morphine is a known pharmaceutical agent that is used in the treatment of pain. Its structure is:
Figure imgf000047_0001
[129] The composition of the invention comprises morphine covalently attached to a peptide.
[130] In the present invention, morphine is covalently attached to the peptide via any of the hydroxyl groups.
Diacetylmorphine
[131] Diacetylmorphine is a known pharmaceutical agent that is used in the treatment of pain. The composition of the invention comprises diacetylmorphine covalently attached to a peptide.
[132] In the present invention, diacetylmorphine or modified diacetylmorphine is covalently attached to the peptide via a linker. This linker may be a small molecule containing 2-6 carbons and one or more functional groups (such as amines, amides, alcohols, or acids) or may be made up of a short chain of either amino acids or carbohydrates.
Dihydromorphine
[133] Dihydromorphine is a known pharmaceutical agent that is used in the treatment of pain. The composition of the invention comprises dihydromorphine covalently attached to a peptide.
[134] In the present invention, dihydromorphine is covalently attached to the peptide via the hydroxyl group. Ethylmorphine
[135] Ethylmorphine is a known pharmaceutical agent that is used in the treatment of pain. The composition of the invention comprises ethylmorphine covalently attached to a peptide.
[136] In the present invention, ethylmorphine is covalently attached to the peptide via the hydroxyl group.
Oxycodone and acetaminophen
[137] Oxycodone and acetaminophen are used together in the treatment of pain.
[138] The composition of the invention comprises oxycodone and acetaminophen covalently attached to a peptide.
Oxycodone
[139] Oxycodone is a known pharmaceutical agent that is used in the treatment of pain. The structure of oxycodone is:
Figure imgf000048_0001
[140] The composition of the invention comprises oxycodone covalently attached to a peptide.
[141] In the present invention, oxycodone is covalently attached to the peptide via a ketone group and a linker. This linker may be a small linear or cyclic molecule containing 2-6 atoms with one or more heteroatoms and one or more functional groups (such as amines, amides, alcohols or acids). For example, glucose would be suitable as a linker. Alternatively, oxycodone may be attached directly through an enolate.
Propoxyphene
[142] Propoxyphene is a known pharmaceutical agent that is used in the treatment of pain. It is a mild narcotic analgesic. It is both commercially available and readily manufactured using published synthetic schemes by those of ordinary skill in the art. The structure of propoxyphene is
Figure imgf000049_0001
[143] The composition of the invention comprises propoxyphene covalently attached to a peptide. In the present invention, propoxyphene or modified propoxyphene is covalently attached to the peptide via a linker. This linker may be a small molecule containing 2-6 carbons and one or more functional groups (such as amines, amides, alcohols, or acids) or may be made up of a short chain of either amino acids or carbohydrates.
Dextroamphetamine
[144] Dextroamphetamine is a known pharmaceutical agent that is used in the treatment of narcolepsy and attention deficit hyperactivity disorder. It is both commercially available and readily manufactured using published synthetic schemes by those of ordinary skill in the art. Its structure is:
Figure imgf000049_0002
[145] In the present invention, dextroamphetamine is covalently attached to the peptide via the amino group.
D-Methylphenidate
[146] D-methylphenidate is a known pharmaceutical agent that is used in the treatment of attention deficit disorder. Its chemical name is ( R,2R)-α-phenyl- 2-piperidineacetic acid methyl ester. Its structure is:
Figure imgf000050_0001
[147] D-methylphenidate is the subject of U.S. Patent Number 2,507,631
(1950) and WO 99/16439 (1999), based on US application Number 937684 (1997), each of which is herein incorporated by reference, which describes how to make that drug.
[148] In the present invention, D-methylphenidate is covalently attached to the peptide via the amino group.
Methylphenidate
[149] Methylphenidate is a known pharmaceutical agent that is used in the treatment of attention deficit disorder. Its structure is:
Figure imgf000050_0002
[150] The composition of the invention comprises methylphenidate covalently attached to a peptide.
[151] In the present invention, methylphenidate is covalently attached to the peptide via the amino group.

Claims

WHAT IS CLAIMED IS:
1. A pharmaceutical composition comprising: a controlled substance; and an amino acid or polypeptide covalently bound to said controlled substance in a manner that renders said controlled substance pharmacologically inactive.
2. The composition of claim 1, wherein said controlled substance is released in active form in the presence of acid present in the stomach or in the presence of enzymes present in the intestinal tract or blood serum.
3. The composition of claim 2, adapted for oral administration, wherein said controlled substance is released in active form in the presence of acid present in the stomach or in the presence of enzymes present in the intestinal tract.
4. The composition of claim 1, wherein said polypeptide comprises less than 70 amino acids.
5. The composition of claim 1, wherein said polypeptide comprises less than 50 amino acids.
6. The composition of claim 1, wherein said polypeptide comprises less than 10 amino acids.
7. The composition of claim 1 wherein said chemical moiety is polyserine.
8. The composition of claim 1 wherein said chemical moiety is bound to said controlled substance by an ester or carbonate bond.
9. The composition of claim 1 wherein said controlled substance is codeine.
10. The composition of claim 1 wherein said controlled substance is fentanyl.
11. The composition of claim 1 wherein said controlled substance is hydrocodone.
12. The composition of claim 1 wherein said controlled substance is hydromorphone.
13. The composition of claim 1 wherein said controlled substance is levorphanol.
14. The composition of claim 1 wherein said controlled substance is methadone.
15. The composition of claim 1 wherein said controlled substance is morphine
16. The composition of claim 1 wherein said controlled substance is oxycodone.
17. The composition of claim 1 wherein said controlled substance is propoxyphene.
18. The composition of claim 1 wherein said controlled substance is sufentanyl.
19. The composition of claim 1 wherein said controlled substance is amphetamine.
20. The composition of claim 1 wherein said controlled substance is methylphenidate.
21. The composition of claim 1 wherein said chemical moiety is a polypeptide.
22. The composition of claim 1 wherein said chemical moiety is an amino acid.
23. The composition of claim 1 wherein said chemical moiety is a protein.
24. The composition of claim 3 that releases said controlled substance in a pharmacologically active form when administered to a human patient by the oral route.
25. The composition of claim 3 that is resistant to release of said controlled substance in a pharmacologically active form when administered by the intranasal route thus diminishing or preventing a euphoric effect.
26. The composition of claim 3 that is resistant to release of said controlled substance in a pharmacologically active form when administered by inhalation thus diminishing or preventing a euphoric effect.
27. A composition of claim 3 that is resistant to release of said controlled substance in a pharmacologically active form when administered by parenteral injection thus diminishing or preventing a euphoric effect.
28. A method for delivering a controlled substance to a patient so as to obtain a therapeutic, but not a substantial euphoric effect, comprising orally administering the composition of claim 1 to said patient.
29. A method for delivering a controlled substance to a patient so as to obtain a therapeutic, but not a substantial euphoric effect, comprising parenterally administering the composition of claim 1 to said patient.
30. A composition of claim 1 wherein the said chemical moiety is an oligopeptide.
31. A composition of claim 30 wherein the said oligopeptide is specifically designed to be cleaved by intestinal enzymes.
PCT/US2003/005525 2001-08-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances WO2003072046A2 (en)

Priority Applications (66)

Application Number Priority Date Filing Date Title
EP03716144.5A EP1531844B1 (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
AU2003219863A AU2003219863C1 (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
CA2477004A CA2477004C (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
KR1020047013136A KR100822498B1 (en) 2002-02-22 2003-02-24 Novel Sustained Release Pharmaceutical Compounds to Prevent Abuse of Controlled Substances
JP2003570793A JP4878732B2 (en) 2002-02-22 2003-02-24 Novel sustained-release pharmaceutical compounds to prevent abuse of controlled substances
IL16366703A IL163667A0 (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to preventabuse of controlled substances
CA2740256A CA2740256A1 (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
ES03716144.5T ES2500117T3 (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent the abuse of controlled substances
US10/858,526 US7105486B2 (en) 2002-02-22 2004-06-01 Abuse-resistant amphetamine compounds
IL163667A IL163667A (en) 2002-02-22 2004-08-22 Conjugates comprising controlled substances covalently bound to peptides or amino acids and compositions comprising same
US10/923,257 US7622441B2 (en) 2002-02-22 2004-08-23 Sustained release pharmaceutical compounds to prevent abuse of controlled substances
US10/953,116 US7375082B2 (en) 2002-02-22 2004-09-30 Abuse-resistant hydrocodone compounds
US10/953,111 US20070066537A1 (en) 2002-02-22 2004-09-30 Compounds and compositions for prevention of overdose of oxycodone
US11/089,056 US20060014697A1 (en) 2001-08-22 2005-03-25 Pharmaceutical compositions for prevention of overdose or abuse
US11/179,801 US8133881B2 (en) 2003-01-13 2005-07-13 Carbohydrate conjugates to prevent abuse of controlled substances
US11/400,304 US7700561B2 (en) 2002-02-22 2006-04-10 Abuse-resistant amphetamine prodrugs
US12/131,923 US7659253B2 (en) 2002-02-22 2008-06-02 Abuse-resistant amphetamine prodrugs
US12/201,982 US7674774B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,820 US20090137673A1 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,907 US7713936B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/202,067 US7687467B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/202,146 US7678771B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,794 US7687466B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,760 US7655630B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/202,159 US7671031B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,586 US7659254B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/202,096 US7718619B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,866 US7662788B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,950 US7671030B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,739 US7678770B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/202,003 US7723305B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/202,941 US20090137487A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,134 US20090137491A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,058 US20090143306A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/202,955 US20090143305A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/202,987 US20090192093A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,133 US20090137490A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,136 US20090209471A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,132 US20090137489A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/202,699 US20090131322A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,108 US20090181898A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/231,489 US20090143307A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/202,845 US20090137486A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,127 US20090131332A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,129 US20090137488A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,137 US20090149392A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/202,777 US20090143304A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/239,221 US20090131324A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,571 US20090137461A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,364 US20090137515A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,600 US20090137677A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,400 US20090186945A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,087 US20090186828A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,554 US20090131335A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,154 US20090131323A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,247 US20090131333A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,479 US20090131334A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,238 US20090131325A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,577 US20090131326A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,429 US20090131476A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,180 US20090186825A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
AU2008229978A AU2008229978B2 (en) 2002-02-22 2008-10-16 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US12/701,483 US20110009669A1 (en) 2002-02-22 2010-02-05 Abuse-resistant amphetamine prodrugs
US12/756,773 US20100197798A1 (en) 2002-02-22 2010-04-08 Abuse-resistant amphetamine prodrugs
US12/881,008 US8343927B2 (en) 2001-08-22 2010-09-13 Pharmaceutical compositions for prevention of overdose or abuse
US13/339,095 US20120115950A1 (en) 2002-02-22 2011-12-28 Abuse-resistant amphetamine prodrugs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35836802P 2002-02-22 2002-02-22
US60/358,368 2002-02-22
US36208202P 2002-03-07 2002-03-07
US60/362,082 2002-03-07

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/156,527 Continuation-In-Part US7060708B2 (en) 1999-03-10 2002-05-29 Active agent delivery systems and methods for protecting and administering active agents
US10/923,088 Continuation-In-Part US7427600B2 (en) 2000-08-22 2004-08-23 Active agent delivery systems and methods for protecting and administering active agents

Related Child Applications (8)

Application Number Title Priority Date Filing Date
US10923257 A-371-Of-International 2003-02-24
PCT/US2004/000646 Continuation-In-Part WO2004062614A2 (en) 2003-01-13 2004-01-13 Carbohydrate conjugates to prevent abuse of controlled substances
US10/857,619 Continuation-In-Part US7223735B2 (en) 2002-02-22 2004-06-01 Abuse resistant lysine amphetamine compounds
US10/858,526 Continuation-In-Part US7105486B2 (en) 2002-02-22 2004-06-01 Abuse-resistant amphetamine compounds
US10/858,526 Continuation US7105486B2 (en) 2002-02-22 2004-06-01 Abuse-resistant amphetamine compounds
US10/923,257 Continuation-In-Part US7622441B2 (en) 2001-08-22 2004-08-23 Sustained release pharmaceutical compounds to prevent abuse of controlled substances
US10/923,088 Continuation-In-Part US7427600B2 (en) 2000-08-22 2004-08-23 Active agent delivery systems and methods for protecting and administering active agents
US10/927,257 Continuation-In-Part US7574503B2 (en) 2004-08-27 2004-08-27 Method and system for using abstract classes to extract status information from networked devices

Publications (2)

Publication Number Publication Date
WO2003072046A2 true WO2003072046A2 (en) 2003-09-04
WO2003072046A3 WO2003072046A3 (en) 2005-03-10

Family

ID=27767540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/005525 WO2003072046A2 (en) 2001-08-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances

Country Status (9)

Country Link
US (1) US7622441B2 (en)
EP (2) EP1531844B1 (en)
JP (1) JP4878732B2 (en)
KR (1) KR100822498B1 (en)
AU (2) AU2003219863C1 (en)
CA (1) CA2477004C (en)
ES (1) ES2500117T3 (en)
IL (2) IL163667A0 (en)
WO (1) WO2003072046A2 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000334A1 (en) 2003-05-29 2005-01-06 New River Pharmaceuticals, Inc. Abuse resistant amphetamine compounds
EP1594513A2 (en) * 2003-01-13 2005-11-16 New River Pharmaceuticals Inc. Carbohydrate conjugates to prevent abuse of controlled substances
EP1675555A2 (en) * 2003-09-30 2006-07-05 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
US7230005B2 (en) * 2003-03-13 2007-06-12 Controlled Chemicals, Inc. Compounds and methods for lowering the abuse potential and extending the duration of action of a drug
EP1812040A2 (en) * 2004-11-08 2007-08-01 New River Pharmaceuticals Inc. Synergistic effects of combined administration of mirtazapine and a stimulant compound
WO2007140272A3 (en) * 2006-05-26 2008-02-14 Pharmacofore Inc Controlled release of phenolic opioids
WO2008101187A2 (en) * 2007-02-16 2008-08-21 Pharmacofore, Inc. Pro-drugs of peripheral phenolic opioid antagonists
WO2008098151A3 (en) * 2007-02-08 2008-12-31 Kempharm Inc Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
EP2101571A1 (en) * 2006-12-11 2009-09-23 Kempharm, Inc. Non-standard amino acid conjugates of amphetamine and processes for making and using the same
WO2011007247A1 (en) 2009-07-17 2011-01-20 Llc Shire Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
US20110129541A1 (en) * 2003-10-27 2011-06-02 Control Delivery Systems, Inc. Suspension delivery system for the sustained and controlled local release of pharmaceuticals
WO2011133346A1 (en) * 2010-04-21 2011-10-27 Pharmacofore, Inc. Peripheral opioid agonists and peripheral opioid antagonists
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US9023860B2 (en) 2007-11-26 2015-05-05 Signature Therapeutics, Inc. Pro-drugs for controlled release of biologically active compounds
EP3380098A4 (en) * 2015-11-29 2019-04-24 John K. Thottathil Novel alpha-hydroxy carboxylic acid and derivatives and other gras based prodrugs of oxycodone and uses thereof
US10449190B2 (en) 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
US10695342B2 (en) 2015-04-27 2020-06-30 Albany Molecular Research, Inc. Methods and compositions for preventing opioid abuse

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20070060500A1 (en) * 2000-08-22 2007-03-15 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
US20090306228A1 (en) * 2000-11-14 2009-12-10 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US8394813B2 (en) * 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US20040156844A1 (en) * 2002-05-22 2004-08-12 Curtis Wright Tamper resistant oral dosage form
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2006055729A1 (en) * 2004-11-16 2006-05-26 Transcutaneous Technologies Inc. Iontophoretic device and method for administering immune response-enhancing agents and compositions
JP2006296511A (en) * 2005-04-15 2006-11-02 Transcutaneous Technologies Inc External preparation, method for applying external preparation, iontophoresis device, and transdermal patch
AR057035A1 (en) * 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
US20070135754A1 (en) * 2005-09-30 2007-06-14 Hidero Akiyama Electrode assembly for iontophoresis for administering active agent enclosed in nanoparticle and iontophoresis device using the same
US20070078375A1 (en) * 2005-09-30 2007-04-05 Transcutaneous Technologies Inc. Iontophoretic delivery of active agents conjugated to nanoparticles
JP2009509677A (en) * 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 Iontophoretic delivery of vesicle encapsulated active substances
WO2007041314A2 (en) * 2005-09-30 2007-04-12 Tti Ellebeau, Inc. Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles
US7848801B2 (en) * 2005-12-30 2010-12-07 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
WO2007120864A2 (en) * 2006-04-14 2007-10-25 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
US20080207668A1 (en) * 2006-10-06 2008-08-28 New River Pharmaceuticals Inc. Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse
PL2124556T3 (en) 2006-10-09 2015-02-27 Charleston Laboratories Inc Pharmaceutical compositions
US20080193514A1 (en) * 2006-11-02 2008-08-14 Transcu Ltd. Compostions and methods for iontophoresis delivery of active ingredients through hair follicles
JPWO2008087803A1 (en) * 2007-01-16 2010-05-06 国立大学法人北海道大学 Liposome preparation for iontophoresis encapsulating antioxidant components
RU2482841C2 (en) * 2007-05-18 2013-05-27 ТиТиАй Эллебо, Инк. Devices for transdermal delivery, providing improved release of active substance through biological surface
JP2010187707A (en) * 2007-06-12 2010-09-02 Hokkaido Univ Liposome preparation for iontophoresis comprising insulin encapsulated therein
ES2692437T3 (en) 2007-08-13 2018-12-03 Abuse Deterrent Pharmaceutical Llc Abuse-resistant drugs, method of use and method of preparation
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
TW201026347A (en) * 2008-09-10 2010-07-16 Transcu Ltd Apparatus and method to dispense HPC-based viscous liquids into porous substrates, e. g., continuous web-based process
ES2414856T3 (en) 2008-12-12 2013-07-23 Paladin Labs Inc. Narcotic drug formulations with decreased addiction potential
BRPI0923836A2 (en) 2008-12-31 2015-07-21 Upsher Smith Lab Inc Opioid-containing oral pharmaceutical compositions and methods
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
UA102916C2 (en) 2009-07-02 2013-08-27 Кемфарм, Інк. Composition based on conjugates of hydrocodone with benzoic acid, benzoic acid or heteroaryl carboxylic acid derivatives, prodrugs and method for treatment of abuses
US20120142720A1 (en) 2009-07-02 2012-06-07 Kempharm, Inc. Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Methods of Making and Use Thereof
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
EP2477610A1 (en) 2009-09-17 2012-07-25 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
WO2011133348A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
AU2012205733B2 (en) 2011-01-11 2015-10-08 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
RU2608305C2 (en) 2011-03-09 2017-01-17 Сигничер Терапьютикс, Инк. Prodrugs of active substances with heterocyclic linkers
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
WO2014146093A2 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
EP3193873A4 (en) * 2014-09-15 2018-05-30 Inspirion Delivery Technologies, LLC Orally administrable compositions and methods of deterring abuse by intranasal administration
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
BR112017011069A2 (en) 2014-11-25 2018-07-10 Kempharm Inc benzoic acid, derivatives and benzoic acid and conjugates of oxycodone heteroaryl carboxylic acid
US9987269B2 (en) 2015-04-27 2018-06-05 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof
EP3423041A4 (en) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. Pharmaceutical compositions
EP3595663A4 (en) * 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
WO2019018638A1 (en) * 2017-07-20 2019-01-24 Suzhou Runxindatai Pharmaceutics Ltd Co. Abuse-resistant long-acting release opioid prodrugs
JP7284764B2 (en) 2018-02-23 2023-05-31 ロデス テクノロジーズ Novel opioid compounds and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843696A (en) 1972-09-05 1974-10-22 Syva Co Methadone analog compounds
US3878187A (en) 1972-09-11 1975-04-15 Syva Co Polypeptide derivatives of amphetamine and analogs for immunoassays
US4025501A (en) 1975-03-20 1977-05-24 Syva Company Polypeptide propoxyphene derivatives for immunoassay reagents
EP0827502A1 (en) 1995-04-03 1998-03-11 Biosite Diagnostics Inc. Methadone derivatives and protein and polypeptide methadone derivative conjugates and labels

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507631A (en) 1944-01-19 1950-05-16 Ciba Pharm Prod Inc Pyridine and piperidine compounds and process of making same
DE1493824A1 (en) * 1964-01-27 1969-05-22 Hoffmann La Roche Process for the preparation of aminocarboxylic acid amides
CH406567A (en) 1964-02-10 1966-01-31 Inventio Ag Device for controlling the setpoint value during the deceleration process in elevators with speed-controlled drives
GB1112347A (en) 1965-08-20 1968-05-01 Pierre Wirth Salts of organic bases with n-carbamyl-l-glutamic acid
US3846399A (en) * 1969-04-10 1974-11-05 Merck & Co Inc Process for controlled stepwise synthesis of polypeptides
US3975342A (en) * 1972-05-15 1976-08-17 Biological Developments, Inc. Tyrosyl-class antigenic conjugates, their preparation and antibodies raised thereto
US3884898A (en) * 1972-08-18 1975-05-20 Syva Co Normorphine derivatives bonded to proteins
US3998799A (en) * 1973-11-02 1976-12-21 Interx Research Corporation Novel, transient pro-drug forms of l-dopa
US4040907A (en) * 1974-06-20 1977-08-09 Syva Company Iodothyronine enzyme conjugates
GB1592552A (en) * 1976-12-10 1981-07-08 Inst Nat Sante Rech Med Pseudopeptides used as medicaments
US4356166A (en) * 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
US4399121A (en) * 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
HU185535B (en) * 1982-05-25 1985-02-28 Mta Koezponti Hivatala Process for preparing new gonadoliberin derivatives
US4457907A (en) * 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
EP0179023B1 (en) * 1984-10-19 1991-01-23 Battelle Memorial Institute With micro-organisms degradable polypeptide, and its use for the progressive release of medicaments
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
IN165717B (en) * 1986-08-07 1989-12-23 Battelle Memorial Institute
DK406686D0 (en) * 1986-08-26 1986-08-26 Hans Bundgaard carboxylic acid derivatives
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5026827A (en) * 1988-09-02 1991-06-25 Matsushita Electric Industrial Co., Ltd. Amphetamine-protein complex as immunogen for obtaining antibodies specific to methamphetamine
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5767227A (en) * 1989-11-03 1998-06-16 Lotus Biochemical Corp. Iodothyronine polymers
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
DE69103503T2 (en) 1990-09-28 1995-01-05 Mercian Corp Adriamycin derivatives.
US5238714A (en) * 1990-10-02 1993-08-24 Board Of Regents, The University Of Texas System Efficient microcapsule preparation and method of use
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2096495C (en) * 1992-06-16 2002-07-09 Kathy Palmer Ordonez Dual analyte immunoassay
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5534496A (en) * 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
GB9215780D0 (en) * 1992-07-24 1992-09-09 Univ London Pharmacy Peptide compounds
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
IL107400A0 (en) 1992-11-10 1994-01-25 Cortech Inc Bradykinin antagonists
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
WO1995012604A1 (en) 1993-11-05 1995-05-11 Aktiebolaget Astra Novel amino acid derivatives
AU5825094A (en) 1993-11-19 1995-06-06 Astra Aktiebolag Novel dipeptide derivatives
GB9401891D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US5847436A (en) * 1994-03-18 1998-12-08 Kabushiki Kaisha Tokai Rika Denki Seisakusho Bipolar transistor having integrated thermistor shunt
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5910569A (en) * 1994-11-22 1999-06-08 Lotus Biochemical Corporation Iodothyronine polymers
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
JP4256932B2 (en) * 1995-06-07 2009-04-22 ジョエル ケイ． スワデッシュ Antigen processing cell target complex
US5762909A (en) * 1995-08-31 1998-06-09 General Electric Company Tumor targeting with polymeric molecules having extended conformation
US5851536A (en) 1995-11-22 1998-12-22 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
NZ332234A (en) * 1996-03-12 2000-06-23 Pg Txl Company Lp Water soluble paclitaxel prodrugs formed by conjugating paclitaxel or docetaxel with a polyglutamic acid polymer and use for treating cancer
GB9606975D0 (en) 1996-04-02 1996-06-05 Univ Birmingham Anti-tumor agent
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
US5970477A (en) * 1996-07-15 1999-10-19 Bellsouth Intellectual Property Management Corporation Method and system for allocating costs in a distributed computing network
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
US6013633A (en) * 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
ATE251913T1 (en) * 1997-05-21 2003-11-15 Univ Leland Stanford Junior COMPOSITION AND METHOD FOR DELAYING TRANSPORT THROUGH BIOLOGICAL MEMBRANES
TW460478B (en) * 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives
JP4465109B2 (en) * 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド Polymer prodrugs of amino and hydroxyl containing bioactive agents
UA53774C2 (en) * 1997-12-22 2003-02-17 Еро-Селтік, С.А. Method of reducing abuse potential of an oral dosage form of opioid analgesic
DE69929173T2 (en) 1998-01-29 2006-08-24 Monash University, Clayton THERAPEUTIC COMPOUNDS
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2000053233A1 (en) * 1999-03-10 2000-09-14 Lotus Biochemical Corporation Use of protein conformation for the protection and release of chemical compounds
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
EP1204406A2 (en) * 1999-07-29 2002-05-15 Roxane Laboratories, Inc. Opioid sustained-released formulation
HU229705B1 (en) * 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US6992076B2 (en) * 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
WO2002028882A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
US20020098999A1 (en) 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
US6740641B2 (en) * 2001-07-27 2004-05-25 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
WO2003024480A2 (en) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DE602004024963D1 (en) * 2003-03-13 2010-02-25 Controlled Chemicals Inc OXYCODON CONJUGATES WITH LOWER ABUSE POTENTIAL AND EXTENDED ACTIVITY

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843696A (en) 1972-09-05 1974-10-22 Syva Co Methadone analog compounds
US3878187A (en) 1972-09-11 1975-04-15 Syva Co Polypeptide derivatives of amphetamine and analogs for immunoassays
US4025501A (en) 1975-03-20 1977-05-24 Syva Company Polypeptide propoxyphene derivatives for immunoassay reagents
EP0827502A1 (en) 1995-04-03 1998-03-11 Biosite Diagnostics Inc. Methadone derivatives and protein and polypeptide methadone derivative conjugates and labels

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1531844A4
TOMKINS, D.M. ET AL., J PHARMACOL EXPERIMENTAL THERAPEUTICS, vol. 280, 1997, pages 1374 - 1382

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1594513A4 (en) * 2003-01-13 2009-02-04 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
EP1594513A2 (en) * 2003-01-13 2005-11-16 New River Pharmaceuticals Inc. Carbohydrate conjugates to prevent abuse of controlled substances
AU2004204804B2 (en) * 2003-01-13 2010-06-24 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
AU2004204804C1 (en) * 2003-01-13 2010-11-18 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US7230005B2 (en) * 2003-03-13 2007-06-12 Controlled Chemicals, Inc. Compounds and methods for lowering the abuse potential and extending the duration of action of a drug
EP1644019A1 (en) * 2003-05-29 2006-04-12 New River Pharmaceuticals Inc. Abuse resistant amphetamine compounds
EP1644019A4 (en) * 2003-05-29 2010-09-01 Shire Llc Abuse resistant amphetamine compounds
EP1644019B2 (en) † 2003-05-29 2018-02-21 Shire LLC Abuse resistant amphetamine compounds
WO2005000334A1 (en) 2003-05-29 2005-01-06 New River Pharmaceuticals, Inc. Abuse resistant amphetamine compounds
JP2007507520A (en) * 2003-09-30 2007-03-29 ニュー リバー ファーマシューティカルズ インコーポレイテッド Pharmaceutical composition for preventing overdose or abuse
EP1675555A4 (en) * 2003-09-30 2011-03-09 Shire Llc Pharmaceutical compositions for prevention of overdose or abuse
EP1675555A2 (en) * 2003-09-30 2006-07-05 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
US20110129541A1 (en) * 2003-10-27 2011-06-02 Control Delivery Systems, Inc. Suspension delivery system for the sustained and controlled local release of pharmaceuticals
EP1812040A2 (en) * 2004-11-08 2007-08-01 New River Pharmaceuticals Inc. Synergistic effects of combined administration of mirtazapine and a stimulant compound
EP1812040A4 (en) * 2004-11-08 2010-05-05 Shire Llc Synergistic effects of combined administration of mirtazapine and a stimulant compound
US8217005B2 (en) 2006-05-26 2012-07-10 Signature Therapeutics, Inc. Controlled release of phenolic opioids
RU2469038C2 (en) * 2006-05-26 2012-12-10 Фармакофор, Инк. Controlled release of phenol opiate
WO2007140272A3 (en) * 2006-05-26 2008-02-14 Pharmacofore Inc Controlled release of phenolic opioids
US8921418B2 (en) 2006-05-26 2014-12-30 Signature Therapeutics, Inc. Controlled release of phenolic opioids
EP2402037A1 (en) * 2006-05-26 2012-01-04 Pharmacofore, Inc. Controlled release of phenolic opioids
EP2101571A4 (en) * 2006-12-11 2010-01-13 Kempharm Inc Non-standard amino acid conjugates of amphetamine and processes for making and using the same
EP2101571A1 (en) * 2006-12-11 2009-09-23 Kempharm, Inc. Non-standard amino acid conjugates of amphetamine and processes for making and using the same
US7776917B2 (en) 2006-12-11 2010-08-17 Mickle Travis C Non-standard amino acid conjugates of amphetamine and processes for making and using the same
US8101661B2 (en) 2006-12-11 2012-01-24 Kempharm, Inc. Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same
US7772222B2 (en) 2007-02-08 2010-08-10 Mickle Travis C Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
WO2008098151A3 (en) * 2007-02-08 2008-12-31 Kempharm Inc Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
EP2433654A3 (en) * 2007-02-08 2013-05-15 Kempharm, Inc. Citrulline and homocitrulline prodrugs of amphetamines and processes for making and using the same
WO2008101187A3 (en) * 2007-02-16 2009-04-16 Pharmacofore Inc Pro-drugs of peripheral phenolic opioid antagonists
WO2008101187A2 (en) * 2007-02-16 2008-08-21 Pharmacofore, Inc. Pro-drugs of peripheral phenolic opioid antagonists
US9023860B2 (en) 2007-11-26 2015-05-05 Signature Therapeutics, Inc. Pro-drugs for controlled release of biologically active compounds
WO2011007247A1 (en) 2009-07-17 2011-01-20 Llc Shire Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
WO2011133346A1 (en) * 2010-04-21 2011-10-27 Pharmacofore, Inc. Peripheral opioid agonists and peripheral opioid antagonists
US10449190B2 (en) 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
US10696683B2 (en) 2015-04-27 2020-06-30 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
US10695342B2 (en) 2015-04-27 2020-06-30 Albany Molecular Research, Inc. Methods and compositions for preventing opioid abuse
US11020386B2 (en) 2015-04-27 2021-06-01 Albany Molecular Research, Inc. Methods and compositions for preventing opioid abuse
EP3380098A4 (en) * 2015-11-29 2019-04-24 John K. Thottathil Novel alpha-hydroxy carboxylic acid and derivatives and other gras based prodrugs of oxycodone and uses thereof

Also Published As

Publication number Publication date
AU2003219863A1 (en) 2003-09-09
EP1531844B1 (en) 2014-08-20
AU2008229978B2 (en) 2012-03-22
EP1531844A2 (en) 2005-05-25
IL163667A (en) 2011-03-31
US7622441B2 (en) 2009-11-24
KR100822498B1 (en) 2008-04-16
EP2319540A1 (en) 2011-05-11
ES2500117T3 (en) 2014-09-30
KR20040095228A (en) 2004-11-12
CA2477004A1 (en) 2003-09-04
IL163667A0 (en) 2005-12-18
CA2477004C (en) 2011-05-10
EP1531844A4 (en) 2007-06-13
AU2003219863C1 (en) 2009-03-05
WO2003072046A3 (en) 2005-03-10
US20050080012A1 (en) 2005-04-14
JP4878732B2 (en) 2012-02-15
JP2005524648A (en) 2005-08-18
AU2003219863B2 (en) 2008-07-31
AU2008229978A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
US7622441B2 (en) Sustained release pharmaceutical compounds to prevent abuse of controlled substances
JP4691500B2 (en) Pharmaceutical composition for preventing overdose or abuse
US7375082B2 (en) Abuse-resistant hydrocodone compounds
US7338939B2 (en) Abuse-resistant hydrocodone compounds
JP2009533459A (en) Compositions and methods for enhancing analgesic action of covalently bound compounds, attenuating harmful side effects and preventing abuse of said compounds
US20070060500A1 (en) Pharmaceutical compositions for prevention of overdose or abuse
US20070203055A1 (en) Compounds and compositions for prevention of overdose of oxycodone
AU2016332071B2 (en) Polysubunit opioid prodrugs resistant to overdose and abuse
KR20060073538A (en) Abuse resistant amphetamine compounds
CA2649360A1 (en) Mono and di-substituted oxycodone compounds and compositions
AU2018234911B2 (en) Polysubunit opioid prodrugs resistant to overdose and abuse
US20070066537A1 (en) Compounds and compositions for prevention of overdose of oxycodone
CA2740256A1 (en) Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
ZA200602598B (en) Pharmaceutical compositions for prevention of overdose or abuse

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2477004

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 163667

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 10923257

Country of ref document: US

Ref document number: 1020047013136

Country of ref document: KR

Ref document number: 2003570793

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003219863

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 01300/KOLNP/2004

Country of ref document: IN

Ref document number: 1300/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003716144

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038087162

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020047013136

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003716144

Country of ref document: EP